pyrazines has been researched along with acipimox in 256 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (8.59) | 18.7374 |
| 1990's | 120 (46.88) | 18.2507 |
| 2000's | 71 (27.73) | 29.6817 |
| 2010's | 35 (13.67) | 24.3611 |
| 2020's | 8 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Alberti, KG; Catalano, C; Farrer, M; Fulcher, GR; Walker, M | 1 |
| Benedetti, S; Chijioke, CP; Pearson, RM | 1 |
| Agius, L; Alberti, KG; Catalano, C; Fulcher, GR; Walker, M | 1 |
| Angelin, B; Berglund, L; Ericsson, S; Eriksson, M | 1 |
| Fattor, B; Musatti, L; Pianezzola, E; Pontiroli, AE; Pozza, G; Strolin Benedetti, M | 1 |
| Beck-Nielsen, H; Vaag, AA | 1 |
| Alberti, KG; Catalano, C; Farrer, M; Fulcher, GR; Thow, J; Walker, M; Whately-Smith, CR | 1 |
| Guglielmone, C; Lanzi, R; Monzani, M; Musatti, L; Pontiroli, AE; Pozza, G | 1 |
| Coates, P; Rees, A; Shuttleworth, D | 1 |
| Nicholls, DP; O'Kane, MJ; Trimble, ER; Trinick, TR; Tynan, MB | 1 |
| Alberti, KG; Farrer, M; Fulcher, GR; Johnson, AJ; Record, CO | 1 |
| Ahonen, J; Ekstrand, A; Grönhagen-Riska, C; Groop, LC; Saloranta, C | 1 |
| Caslake, MJ; Gaw, A; Griffin, BA; Packard, CJ; Shepherd, J; Yip, B | 1 |
| Alberti, KG; Cooper, BG; Elliott, C; Orskov, H; Reed, JW; Walker, M | 1 |
| Lanzi, R; Monti, LD; Pontiroli, AE; Pozza, G; Sandoli, E | 1 |
| Noacco, C; Taboga, C; Tonutti, L | 1 |
| Cvrkalová, A; Hanzen, E; Klimes, I; Kréze, A; Lacko, A; Langrová, H; Rajecová, E | 1 |
| Davidoff, P; García de los Ríos, M; González, G; Ruiz, F; Silva, MA; Tapia, JC; Varas, MA | 1 |
| Ekstrand, A; Franssila-Kallunki, A; Groop, L; Saloranta, C; Taskinen, MR | 2 |
| Beck-Nielsen, H; Damsbo, P; Gall, MA; Richter, EA; Skött, P; Vaag, A | 1 |
| Tornvall, P; Walldius, G | 1 |
| Bellosta, S; Bernini, F; Franceschini, G; Fumagalli, R; Michelagnoli, S; Pazzucconi, F; Sirtori, CR; Torre, C; Vaccarino, V | 1 |
| Angelin, B; Ericsson, S; Eriksson, M | 1 |
| Edlund, A; Musatti, L; Wennmalm, A | 1 |
| Lanzi, R; Monti, LD; Pontiroli, AE; Pozza, G | 1 |
| Bellosta, S; Bernini, F; Franceschini, G; Fumagalli, R; Michelagnoli, S; Sirtori, CR; Vaccarino, V | 1 |
| Bain, SC; Barnett, AH; Jones, AF | 1 |
| al-Shurbaji, A; Berglund, L; Björkhem, I | 1 |
| Barlow, CW; Jankelow, D; Myburgh, DP; Soicher, ER | 1 |
| Bedford, DK; Gaw, A; Kilday, C; Lorimer, AR; Packard, CJ; Series, JJ; Shepherd, J | 1 |
| Bremer, JM; Lintott, CJ; Scott, RS | 1 |
| Gylling, H; Miettinen, TA; Vanhanen, H | 1 |
| Cortese, C; Gnasso, A; Iannaci, G; Lamenza, F; Montefusco, S; Postiglione, A | 1 |
| Nikkilä, EA; Taskinen, MR | 1 |
| Avogaro, P; Crepaldi, G; Descovich, GC; Di Perri, T; Musatti, L; Postiglione, A; Sirtori, CR; Strano, A; Ventura, S | 1 |
| Celotti, F; de Paolis, C; Farina, R; Pianezzola, E; Pontiroli, AE; Valzelli, G | 1 |
| Ball, MJ; Galton, D; Jones, DB; Mann, JI; Rechlass, JP; Stirling, C; Vella, M | 1 |
| Demacker, PN; Stalenhoef, AF; Stuyt, PM; Van 't Laar, A | 1 |
| Betteridge, DJ; Campbell, RR; Foster, K; McAleer, M; Mundy, D; Reckless, JP; Stirling, C | 1 |
| Bergamini, E; Locci Cubeddu, T; Masiello, P; Pollera, M | 1 |
| Bonadonna, A; Bruno, R; Cascone, C; De Luca, M; Maggi, E; Munaretto, G; Tamassia, V | 1 |
| de Castilho, LN; Quintão, EC | 1 |
| Branzoli, U; Chiari, A; Lovisolo, PP; Orsini, G | 1 |
| Jung, W; Kohlmeier, M; Nikolaus, T; Schlierf, G | 1 |
| Aktories, K; Jakobs, KH; Schultz, G | 1 |
| Angelucci, R; Briatico-Vangosa, G; Lovisolo, PP; Orsini, G; Ronchi, R; Valzelli, G | 1 |
| Maggi, E; Pianezzola, E; Valzelli, G | 1 |
| Cairoli, R; Fragiacomo, C; Noseda, G | 1 |
| Bergamini, E; Locci-Cubeddu, T | 1 |
| Maggi, E; Moro, E; Musatti, L; Tamassia, V; Valzelli, G | 1 |
| Angelucci, R; Briatico-Vangosa, G; Lovisolo, PP; Orsini, G; Ronchi, R | 1 |
| Fuccella, LM; Goldaniga, G; Lovisolo, P; Maggi, E; Mandelli, V; Musatti, L; Sirtori, CR | 1 |
| Cho, JH; Huh, KB; Kim, KR; Lee, EJ; Lee, HC; Lim, SK; Nam, MS; Nam, SY; Song, YD | 2 |
| Kim, JY; Kim, YW; Lee, SK | 1 |
| Aguirre, C; Araya, V; Contreras, P; Zura, ML | 1 |
| Hortobágyi, J; Schneider, I; Zahorcsek, Z | 1 |
| Bielak, G; Grossmann, G; Miturzyńska-Stryjecka, H; Widomska-Czekajska, T | 1 |
| Bobbio, M; Bongioanni, S; Bonzano, A; Caruzzo, C; Caruzzo, E; Civaia, F; Liboni, W | 1 |
| Fazio, F; Landoni, C; Lucignani, G; Monti, LD; Moresco, RM; Piatti, P; Pozza, G; Stefani, I | 1 |
| Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW | 1 |
| Haaparanta, M; Knuuti, MJ; Nuutila, P; Raitakari, M; Ruotsalainen, U; Solin, O; Teräs, M; Voipio-Pulkki, LM; Wegelius, U; Yki-Järvinen, H | 1 |
| Vítková, D; Zák, A; Zeman, M | 1 |
| Andreotti, AC; Caumo, A; Lanzi, R; Manzoni, MF; Moreschi, A; Pontiroli, AE | 1 |
| Jéquier, E; Nicod, P; Paquot, N; Randin, D; Scherrer, U; Schneiter, P; Tappy, L; Vollenweider, L; Vollenweider, P | 1 |
| Cummings, MH; Watts, GF | 1 |
| Agroyannis, B; Chondros, K; Exarchos, D; Kapetanaki, A; Konstadinidou, I; Koutsikos, D; Tsoutsos, D; Tzanatos, H | 1 |
| Cathelineau, G; Gautier, JF; Jandrain, B; Lacroix, M; Lefèbvre, PJ; Mosora, F; Pirnay, F; Scheen, AJ | 1 |
| Dhalla, NS; Elimban, V; Rupp, H | 1 |
| Alberti, G; Record, CO; Shmueli, E; Walker, M | 1 |
| Hermann, M; Hromadová, M; Klimes, I; Minchenko, A; Mitková, A; Seböková, E | 1 |
| Beck-Nielsen, H; Henriksen, JE; Melander, A; Thye-Rønn, P; Vaag, A; Worm, D | 1 |
| Bergman, J; Haaparanta, M; Härkönen, R; Hartiala, J; Knuuti, MJ; Mäki, M; Nuutila, P; Ruotsalainen, U; Teräs, M; Voipio-Pulkki, LM; Wegelius, U; Yki-Järvinen, H | 1 |
| Knight, BL; O'Connor, B; O'Donnell, M; Perombelon, N; Reaveley, D; Seed, M | 1 |
| Brambilla, E; Franceschini, G; Gianfranceschi, G; Pazzucconi, F; Sirtori, CR | 1 |
| Chojnowska-Jezierska, J; Jabłoński, S; Tkaczewski, W | 1 |
| Puhakainen, I; Yki-Järvinen, H | 1 |
| Bolli, GB; Brunetti, P; Ciofetta, M; Di Vincenzo, A; Epifano, L; Fanelli, C; Lepore, M; Modarelli, F; Pampanelli, S | 1 |
| Ekstrand, A; Eriksson, J; Franssila-Kallunki, A; Groop, L; Saloranta, C; Taskinen, MR | 1 |
| Currie, R | 1 |
| Babic, D; Cvrkalová, AL; Klimes, I; Koev, D; Langrová, H; Profozic, V; Rajecová, E; Skrabalo, Z; Susic, M; Zlateva, S | 1 |
| Groop, L; Härkönen, M; Melander, A; Saloranta, C; Taskinen, MR; Widen, E | 1 |
| Balogh, Z; Boda, J; Juhász, A; Leövey, A; Mohácsi, A; Paragh, G | 1 |
| Barter, PJ; Liang, HQ; Rajaram, OV; Rye, KA | 1 |
| Braatvedt, G; Corrall, RJ; Newrick, PG; Stansbie, D | 1 |
| Alberti, KG; Berrish, TS; Cooper, BG; Elliott, C; Orskov, H; Reed, JW; Walker, M | 1 |
| Alberti, KG; Farrer, M; Fulcher, GR; Johnson, AS; Walker, M | 1 |
| Akanji, AO; Hockaday, TD; Kirk, M; Osifo, E | 1 |
| Agius, L; Alberti, KG; Orskov, H; Walker, M | 1 |
| Cramb, R; Head, A; Jakeman, PM; Kendall, MJ; Maxwell, S | 1 |
| Scheen, AJ | 1 |
| Boffano, GM; Camanni, F; Ghigo, E; Grottoli, S; Maccario, M; Oleandri, SE; Procopio, M; Taliano, M | 1 |
| Cho, JH; Huh, KB; Kim, KR; Lee, HC; Nam, MS; Nam, SY | 1 |
| Alberti, KG; Christie, AW; Emmison, N; Kraemer, FB; McCormick, DK; Yeaman, SJ | 1 |
| Alberti, KG; Brown, MD; Conti, M; Davis, SN; Monti, LD; Piatti, PM; Pozza, G | 1 |
| Liang, J; Yu, Y; Zhang, X | 1 |
| Anh-Le, N; Bodkin, NL; Hannah, JS; Hansen, BC; Howard, BV; Paidi, MS | 1 |
| Alvarez, CV; Casanueva, FF; Cordido, F; Dieguez, C; Peino, R; Peñalva, A | 2 |
| Groop, L; Saloranta, C | 1 |
| Lanzi, R; Malighetti, ME; Manzoni, MF; Pontiroli, AE | 1 |
| Hong, SK; Kim, CH; Lee, KU; Park, JY; Park, KS; Park, SW; Suh, KI | 1 |
| Balasse, EO; Féry, F; Melot, C; Plat, L | 1 |
| Bax, JJ; Cornel, JH; Heine, RJ; van Lingen, A; Veening, MA; Visser, CA; Visser, FC | 1 |
| Luley, C; Orth, M | 1 |
| Balasse, EO; Baleriaux, M; Fery, F; Plat, L | 1 |
| Birkenhäger, JC; De Heide, L; Deckers, JW; Hoogerbrugge, N; Jansen, H; Zillikens, MC | 2 |
| Fogari, R; Lusardi, P; Marasi, G; Preti, P; Vanasia, A; Zoppi, A | 1 |
| Bax, JJ; Cornel, JH; Fioretti, PM; Krenning, EP; Poldermans, D; Rambaldi, R; Valkema, R; van Lingen, A; Visser, FC | 1 |
| Emery, PW; Obeid, OA | 1 |
| Andreotti, AC; Bianchi, E; Caumo, A; Lanzi, R; Luzi, L; Malighetti, ME; Manzoni, MF; Pontiroli, AE; Sereni, LP | 1 |
| Ho, LT; Hsiao, LC; Hwu, CM; Kwok, CF; Li, SH; Liu, YF; Shih, KC | 1 |
| Astorga, R; Casanueva, FF; Dieguez, C; Fernandez-Lopez, I; Jimenez, LM; Leal-Cerro, A | 1 |
| Mir, MA; Oleesky, DA | 1 |
| Bolli, GB | 1 |
| D'Onofrio, F; Gambardella, A; Gentile, S; Gualdiero, P; Manzella, D; Paolisso, G; Rizzo, MR; Tagliamonte, MR; Varricchio, M; Verza, M | 1 |
| Collins, SM; Gaw, A; Lindsay, GM; Lorimer, AR; Packard, CJ; Shepherd, J | 1 |
| Balogh, Z; Boda, J; Kárpáti, L; Kovács, P; Leövey, A; Paragh, G; Szabó, J | 1 |
| Alberti, KG; Davoren, PM; Gries, FA; Hubinger, A; Kelly, W; Whately-Smith, C | 1 |
| Fitili, C; Mavromatidis, K; Sombolos, K | 1 |
| Bedford, D; Caslake, M; Malmström, R; Packard, CJ; Shepherd, J; Stewart, P; Taskinen, MR; Yki-Järvinen, H | 1 |
| D'Onofrio, F; Gambardella, A; Giugliano, D; Gualdiero, P; Howard, BV; Paolisso, G; Rizzo, MR; Saccomanno, F; Tagliamonte, MR | 1 |
| Casanueva, FF; Considine, RV; Cordido, F; Dieguez, C; Fernández Alvarez, J; Peinò, R; Peñalva, A; Rodriguez-Garcia, J; Rodriguez-Segade, S | 1 |
| Chan, DC; Chow, CC; Cockram, CS; Ko, GT; Lam, CW; Mak, TW; Tsang, LW; Yeung, VT | 1 |
| Otto, C; Parhofer, KG; Richter, WO; Ritter, MM; Schwandt, P | 1 |
| Casanueva, FF; Cordido, F; Dieguez, C; Fernandez, T; Martinez, T; Peinó, R; Peñalva, A | 1 |
| Kleinjans, HA; Stalenhoef, AF; Stuyt, PM | 1 |
| Brouwer, EM; Saris, WH; Schiffelers, SL; van Baak, MA | 1 |
| Bowness, RJ; Hardman, AE; Macdonald, IA; Malkova, D | 1 |
| Marks, V; Morgan, L; Norris, F; Ranganath, L; Wright, J | 2 |
| Caumo, A; Lanzi, R; Losa, M; Mignogna, G; Pontiroli, AE | 1 |
| Algra, A; Banga, JD; de Bruint, TW; Erkelens, DW; Kanters, SD | 1 |
| Dullaart, RP; Riemens, SC; Sluiter, WJ; van Tol, A | 1 |
| Boden, G; Rocha, DM; Santomauro, AT; Santos, RF; Silva, ME; Strassmann, PG; Ursich, MJ; Wajchenberg, BL | 1 |
| Andreotti, AC; Caumo, A; Lanzi, R; Luzi, L; Malighetti, ME; Manzoni, MF; Pontiroli, AE; Sereni, LP | 1 |
| Cho, BY; Kim, CH; Kim, SY; Lee, HK; Lee, MK; Park, DJ; Park, KS; Shin, CS | 1 |
| Baum, RP; Hertel, A; Hör, G; Schröder, O | 1 |
| Alcocer, L; Campos, E; Fernández, L; Más, R | 1 |
| Fritsche, A; Häring, H; Lehmann, R; Renn, W; Stumvoll, M; Tschritter, O; Wahl, HG | 1 |
| Arvat, E; Daga, GA; De Bacco, C; Fassino, S; Ghigo, E; Gianotti, L; Lanfranco, F; MacCario, M; Ramunni, J | 1 |
| Hamood, H; Morad, N; Naschitz, J; Yeshurun, D | 1 |
| Beck-Nielsen, H; Henriksen, JE; Vaag, A; Vinten, J; Worm, D | 1 |
| Bolscher, E; Casanueva, FF; de Vries, WR; Dieguez, C; Koppeschaar, HP; Niesink, M; Smid, HE; Van Dam, PS; Waasdorp, EJ | 1 |
| Andrianov, V; Kalvinsh, I; Lang, H; Lorenzen, A; Schwabe, U; Stannek, C | 1 |
| Choong, B; Cooney, GJ; Cooper, GJ; Iglesias, MA; Kraegen, EW; Lim-Fraser, M; Watson, DG; Ye, JM | 1 |
| Casanueva, FF; Cordido, F; Dieguez, C; Martinez, T; Peñalva, A | 1 |
| Ackermans, MT; Endert, E; Romijn, JA; Sauerwein, HP; Sprangers, F | 1 |
| Ahrén, B | 1 |
| Dullaart, RP; van Tol, A | 1 |
| Blachère, JC; Bukowiecki, LJ; Pérusse, F | 1 |
| Christiansen, JS; Jørgensen, JO; Møller, N; Nielsen, S | 1 |
| Belosi, C; Cento, RM; Ciampelli, M; Lanzone, A; Leoni, F; Muzj, G; Romualdi, D | 1 |
| Matzinger, O; Schneiter, P; Tappy, L | 1 |
| Bramnert, M; Groop, LC; Laurila, E; Manhem, P; Segerlantz, M | 2 |
| Apa, R; Ciampelli, M; Guido, M; Lanzone, A; Lattanzi, F; Leoni, F | 1 |
| Christiansen, JS; Jørgensen, JO; Møller, N; Nielsen, S; Pedersen, SB | 1 |
| Guo, W; Han, J; Wang-Fisher, YL | 1 |
| Christiansen, JS; Hartmund, T; Jørgensen, JO; Møller, N; Nair, KS; Nielsen, S; Nørrelund, H | 1 |
| Häring, HU; Kausch, C; Lammers, R; Staiger, H; Stumvoll, M; Tschritter, O | 1 |
| Bjerve, KS; Grill, VE; Mostad, IL; Qvigstad, E | 1 |
| Barnes, AA; Brown, AJ; Dowell, SJ; Eilert, M; Elshourbagy, N; Foord, SM; Fraser, NJ; Green, A; Hassall, DG; Ignar, DM; Marshall, FH; Murdock, PR; Pike, NB; Steplewski, K; Szekeres, PG; Wilson, S; Wise, A | 1 |
| Aliabadi, N; Breu, J; Grinspoon, S; Hadigan, C; Meininger, G; Rabe, J | 1 |
| Bax, JJ; Boersma, E; Kam, BL; Krenning, EP; Poldermans, D; Rambaldi, R; Reijs, AE; Rietveld, T; Roelandt, JR; Valkema, R | 1 |
| Casanueva, FF; Cordido, F; de Vries, WR; Dieguez, C; Koppeschaar, HP; van Dam, PS; van Thiel, E; Veldhuyzen, BF | 1 |
| Furuichi, K; Hiyama, H; Kamohara, M; Matsumoto, S; Matsuo, A; Matsushime, H; Ohishi, T; Saito, T; Soga, T; Takasaki, J | 1 |
| Bax, JJ; Bountioukos, MA; Elhendy, A; Krenning, EP; Poldermans, D; Roelandt, JR; Schinkel, AF; Valkema, R; van Domburg, RT; Vourvouri, EC | 1 |
| Hesselink, MK; Hoeks, J; Hul, GB; Saris, WH; Schrauwen, P; van Baak, MA; Vidal, H | 1 |
| Alvarez-Castro, P; Casanueva, FF; Cordido, F; Dieguez, C; Isidro, ML | 1 |
| Christiansen, JS; Frystyk, J; Ivarsen, P; Jørgensen, JO; Møller, N; Nair, KS; Nielsen, S; Nørrelund, H | 1 |
| Alvarez, P; Casanueva, FF; Cordido, F; Dieguez, C; Isidro, L; Leal-Cerro, A; Peinó, R | 1 |
| Breu, J; Canavan, B; Grinspoon, S; Koutkia, P; Meininger, G | 1 |
| Buijs, MM; Frölich, M; Kok, P; Kok, SW; Meinders, AE; Pijl, H; Roelfsema, F; Van Ierssel, IH; Voshol, PJ | 1 |
| Bernstein, EL; Breu, J; Canavan, B; Grinspoon, S; Koutkia, P; Ljungquist, K | 1 |
| Ackermans, MT; canh Hung, N; Endert, E; Kager, PA; Sauerwein, HP; van Thien, H; Weverling, GJ | 1 |
| Christiansen, JS; Jørgensen, JO; Møller, N; Nielsen, S; Nørrelund, H | 1 |
| Bergamini, E; Carresi, C; Cavallini, G; Donati, A; Gori, Z; Parentini, I | 1 |
| Ackermans, MT; Allick, G; Bisschop, PH; Endert, E; Meijer, AJ; Romijn, JA; Sauerwein, HP; Sprangers, F; Weverling, GJ | 1 |
| Buijs, MM; Frölich, M; Kok, P; Kok, SW; Meinders, AE; Pijl, H; Roelfsema, F; Stokkel, MP; Westenberg, JJ | 1 |
| Layden, JD; Malkova, D; Nimmo, MA | 1 |
| Bajaj, M; Cusi, K; DeFronzo, RA; Kashyap, S; Mandarino, L; Suraamornkul, S | 1 |
| Cameron-Smith, D; Keizer, HA; Koopman, R; Manders, R; McAinch, AJ; Punyadeera, C; Smit, E; van Loon, LJ; Zorenc, AH | 1 |
| Carey, PE; Cline, GW; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Taylor, R | 1 |
| Gijsen, AP; Kaastra, B; Keizer, HA; Koopman, R; Manders, RJ; Saris, WH; Stegen, JH; van Loon, LJ | 1 |
| Dullaart, RP; Meinardi, JR; Riemens, SC; Sluiter, WJ; Wolffenbuttel, BH | 1 |
| Christiansen, JS; Hansen, TK; Jorgensen, JO; Moller, N; Nielsen, S; Vestergaard, ET | 1 |
| Bai, HJ; Nie, SF; Pan, WS; Yang, XG; Zhang, GJ | 1 |
| Bajaj, M; Cline, GW; DeFronzo, RA; Mandarino, LJ; Romanelli, A; Shulman, GI; Suraamornkul, S | 1 |
| Christiansen, JS; Gjedde, S; Gjedsted, J; Gormsen, LC; Jørgensen, JO; Møller, N; Nielsen, S; Vestergaard, ET | 1 |
| Braun, EJ; McMurtry, JP; Sweazea, KL | 1 |
| Cutfield, WS; Gluckman, PD; Hofman, PL; Lobie, PE; Vickers, MH | 1 |
| Andersen, R; Grinspoon, S; Hadigan, C; Liebau, J; Torriani, M | 1 |
| Kurbanov, RD; Shek, AB; Tashkenbaeva, NF | 1 |
| Airaksinen, KE; Engblom, E; Hesse, B; Iozzo, P; Knuuti, J; Någren, K; Naum, A; Nuutila, P; Opie, LH; Tuunanen, H; Ukkonen, H | 1 |
| Ballal, K; Taegtmeyer, H | 1 |
| Cameron-Smith, D; Hargreaves, M; McAinch, AJ; Tunstall, RJ; van Loon, LJ | 1 |
| Ijzerman, AP; Soudijn, W; van Wijngaarden, I | 1 |
| Bajaj, M; Cersosimo, E; Cusi, K; Gastaldelli, A; Kashyap, S | 1 |
| Bajaj, M; DeFronzo, RA; Mandarino, LJ; Medina-Navarro, R; Meyer, C; Suraamornkul, S | 1 |
| Arsos, G; de Haas, M; de Klerk, J; de Vrey, E; Weijs, L | 1 |
| Ditlevsen, S; Frøsig, C; Lindegaard, B; Mittendorfer, B; Pedersen, BK; Petersen, AM; Plomgaard, P; Van Hall, G; Wojtaszewski, JF | 1 |
| Christiansen, JS; Gjedde, S; Gjedsted, J; Gormsen, LC; Jørgensen, JO; Møller, N; Nørrelund, H; Schmitz, O | 1 |
| Eisendle, K; Fritsch, P; Linder, D; Philipp, W; Piza, H; Ratzinger, G; Schmuth, M; Zelger, B | 1 |
| Borra, R; Iozzo, P; Kankaanpaa, M; Knuuti, J; Lehto, HR; Någren, K; Naum, AG; Nuutila, P; Parkkola, R; Rigazio, S; Simi, C; Tuunanen, H | 1 |
| Bax, JJ; de Boer, HH; de Roos, A; Hammer, S; Lamb, HJ; Romijn, JA; Smit, JW; van der Meer, RW | 1 |
| Chassin, LJ; Dunger, DB; Hill, N; Hovorka, R; Humphreys, SM; Lunn, DJ; Marcovecchio, ML; Salgin, B | 1 |
| Acerini, CL; Bluck, LJ; Dunger, DB; Humphreys, SM; Jackson, SJ; Marcovecchio, ML; Salgin, B; Williams, RM | 1 |
| Bhasin, S; Guo, W; Hamilton, JA; Hruz, PW; Hua, N; Jasuja, R; Jiang, L; Miller, A; Pudney, J; Wong, S | 1 |
| Cefali, E; Connor, A; Menon, R; Wilding, I; Wray, H | 1 |
| Boutley, H; Fay, R; Karcher, G; Lacolley, P; Marie, PY; Maskali, F; Maureira, P; Person, C; Poussier, S; Régnault, V; Tran, N | 1 |
| Cattaneo, A; Cavagnini, F; Fatti, LM; Filippini, B; Grasso, A; Moro, M; Orsini, F; Pecori Giraldi, F; Scacchi, M | 1 |
| Bøtker, HE; Eiskjær, H; Gøtzsche, L; Halbirk, M; Møller, N; Nielsen, R; Nielsen, SS; Nielsen, TT; Nielsen-Kudsk, JE; Nørrelund, H; Schmitz, O; Wiggers, H | 1 |
| Hainer, V; Hill, M; Nedvidkova, J; Papezova, H; Smitka, K; Vondra, K | 2 |
| Bergamini, E; Bertolotto, M; Dallegri, F; Delrio, A; Franciosi, U; Lenglet, S; Mach, F; Minetti, S; Montecucco, F; Ottonello, L; Pelli, G; Pende, A; Puddu, A; Quercioli, A; Viviani, GL; Vuilleumier, N | 1 |
| Hollingsworth, KG; Lim, EL; Smith, FE; Taylor, R; Thelwall, PE | 1 |
| Bousquenaud, M; Boutley, H; Devaux, Y; Karcher, G; Marie, PY; Maskali, F; Poussier, S; Wagner, DR | 1 |
| Chai, J; Choudhury, RP; Digby, JE; Greaves, DR; Jefferson, A; Martinez, F; Ruparelia, N; Wamil, M | 1 |
| Borra, R; Iozzo, P; Knuuti, J; Lehto, HR; Lepomaki, V; Nuutila, P; Pärkkä, J; Parkkola, R; Tuunanen, H | 1 |
| Jiang, S; Jin, F; Li, K; Ma, S; Yang, D; Yang, Y; Zhang, X; Zhang, Y | 1 |
| Deldicque, L; Francaux, M; Raymackers, JM; van Loon, LJ; Zbinden-Foncea, H | 1 |
| Chen, R; Guo, R; Huang, J; Li, R; Liu, X; Wang, B; Wei, C; Yuan, G | 1 |
| Andersen, KF; Divilov, V; Koziorowski, J; Lewis, JS; Pillarsetty, N | 1 |
| Defronzo, RA; Dubé, JJ; Espinoza, S; Liang, H; Mohan, S; Musi, N; Shanmugasundaram, K; Sriwijitkamol, A; Tantiwong, P | 1 |
| Ditlevsen, S; Lindegaard, B; Mittendorfer, B; Pedersen, BK; Plomgaard, P | 1 |
| Abdul-Ghani, M; Clarke, GD; Daniele, G; DeFronzo, RA; Eldor, R; Merovci, A; Taranova, A; Tripathy, D; Xiong, J | 1 |
| Boutley, H; Karcher, G; Lacolley, P; Lhuillier, M; Louis, H; Marie, PY; Maskali, F; Poussier, S; Thornton, SN | 1 |
| Friedman, TC; Ivey, R; Lee, D; Shin, CS; Sinha-Hikim, AP; Sinha-Hikim, I | 1 |
| Jensen, J; Jessen, N; Jørgensen, JO; Nellemann, B; Nielsen, S; Pedersen, SB; Søndergaard, E | 1 |
| Coen, PM; Goodpaster, BH | 1 |
| Auwerx, J; Bierwagen, A; Bilet, L; Havekes, B; Hesselink, MK; Hwang, JH; Livingstone, R; Moullan, N; Nowotny, P; Paglialunga, S; Phielix, E; Pirinen, E; Roden, M; Ropelle, ER; Schrauwen, P; Schrauwen-Hinderling, VB; Sparks, LM; Szendroedi, J; van de Weijer, T; Williams, EG | 1 |
| Canu, T; De Cobelli, F; Del Maschio, A; Esposito, A; Fragasso, G; Lattuada, G; Manzoni, G; Margonato, A; Perseghin, G; Salerno, A | 1 |
| Sekhar, RV | 1 |
| Dai, X; Foretz, M; Liu, J; Liu, Z; Lu, Q; Ouyang, C; Song, P; Viollet, B; Wu, J; Wu, Y; Xie, Z; Yuan, Z; Zhang, W; Zhao, Z; Zhuo, X; Zou, MH | 1 |
| Braun, LR; De Sousa-Coelho, AL; Feldpausch, MN; Frontera, WR; Grinspoon, SK; Lee, H; Looby, SE; Makimura, H; Patti, ME; Stanley, TL; Suresh, C; Syu, S; Torriani, M | 1 |
| Abdul-Ghani, M; Daniele, G; DeFronzo, RA; Mari, A; Merovci, A; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Koc, M; Polak, J; Seda, O; Shimoda, LA; Weiszenstein, M | 1 |
| Anderwald, CH; Baumgartner-Parzer, S; Fürnsinn, C; Harreiter, J; Kosi-Trebotic, L; Krebs, M; Krssak, M; Luger, A; Smajis, S; Trattnig, S; Winhofer, Y; Wolf, P | 1 |
| Cichosz, SL; Fleischer, J; Jørgensen, JOL; Møller, N; Vestergaard, ET | 1 |
| Cicalini, S; D'Abbraccio, M; d'Ettorre, G; Di Biagio, A; Maggi, P; Martinelli, C; Nunnari, G; Rusconi, S; Sighinolfi, L; Spagnuolo, V; Squillace, N | 1 |
| Hansen, D; Minten, L; Smeets, K; van Dijk, JW; van Loon, LJC; Verboven, K; Verdijk, LB; Zorenc, A | 1 |
| Jessen, N; Johannsen, M; Jørgensen, JO; Møller, AB; Møller, N; Rittig, N; Thomsen, HH | 1 |
| Gribble, FM; Hjelholt, AJ; Holst, JJ; Jessen, N; Jørgensen, JOL; Kuhre, RE; Larraufie, P; Møller, N; Reimann, F; Vestergaard, ET | 1 |
| Abdullahi, A; Auger, C; Barayan, D; Jeschke, MG; Knuth, CM; Vinaik, R | 1 |
| Aday, AW; Beckman, JA; Goldfine, AB; Gregory, JM | 1 |
| Hjelholt, AJ; Jessen, N; Jørgensen, JOL; Møller, N; Pedersen, SB; Søndergaard, E | 1 |
| Charidemou, E; Griffin, JL; Gudiksen, A; Hjelholt, AJ; Jessen, N; Jørgensen, JOL; Møller, N; Pedersen, SB; Pilegaard, H | 1 |
| Campanella, M; Faccenda, D; Singh, A | 1 |
| Mori, M; Supuran, CT | 1 |
| Huang, W; Liu, X; Wu, L; Yang, B | 1 |
| Abouhajar, A; Alcock, L; Bigirumurame, T; Bradley, P; Brown, L; Campbell, I; Del Din, S; Faitg, J; Falkous, G; Gorman, GS; Lakey, R; McFarland, R; Newman, J; Rochester, L; Ryan, V; Smith, H; Steel, A; Stefanetti, RJ; Su, H; Taylor, RW; Thomas, NJP; Tuppen, H; Vincent, AE; Warren, C; Watson, G | 1 |
| Deng, H; Gao, Y; Lai, C; Li, G; Shen, X; Wang, L; Wang, N; Yu, H; Zhou, L; Zhou, W | 1 |
9 review(s) available for pyrazines and acipimox
| Article | Year |
|---|---|
Acipimox--a nicotinic acid analogue for hyperlipidaemia.
Topics: Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrazines | 1991 |
[Effect of acipimox on diabetes mellitus-associated hyperlipoproteinemia].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines | 1993 |
Interactions between glucose and FFA metabolism in man.
Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipolysis; Models, Biological; Niacin; Obesity; Pyrazines | 1996 |
FDG SPECT in the assessment of myocardial viability. Comparison with dobutamine echo.
Topics: Cardiotonic Agents; Deoxyglucose; Dobutamine; Echocardiography; Exercise Test; Fluorodeoxyglucose F18; Glucose; Humans; Hypolipidemic Agents; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Predictive Value of Tests; Pyrazines; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 1997 |
No low-fat diet for the failing heart?
Topics: Cardiac Output, Low; Diet, Fat-Restricted; Energy Metabolism; Humans; Hypolipidemic Agents; Myocardium; Pyrazines; Stroke Volume | 2006 |
Nicotinic acid receptor subtypes and their ligands.
Topics: Adipocytes; Amino Acid Sequence; Animals; Humans; Ligands; Lipolysis; Molecular Sequence Data; Niacin; Nicotinic Agonists; Pyrazines; Receptors, G-Protein-Coupled; Receptors, Nicotinic; Sequence Alignment; Tissue Distribution | 2007 |
Treatment of dyslipidemia in HIV.
Topics: Anti-HIV Agents; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diet Therapy; Dyslipidemias; Exercise Therapy; Ezetimibe; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Fibric Acids; Glutathione; Growth Hormone-Releasing Hormone; HIV Infections; Human Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Niacin; Pyrazines; Thiazolidinediones; Triglycerides | 2015 |
Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
Topics: Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Growth Hormone-Releasing Hormone; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipodystrophy; Pyrazines; Risk Factors | 2017 |
Pharmacological advances in mitochondrial therapy.
Topics: Antioxidants; Humans; Mitochondria; Mitochondrial Diseases; Mitochondrial Dynamics; Neurodegenerative Diseases; Oxidative Phosphorylation; Pyrazines; Ubiquinone | 2021 |
133 trial(s) available for pyrazines and acipimox
| Article | Year |
|---|---|
Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesterified; Glucagon; Glycerol; Humans; Hydrocortisone; Hydroxybutyrates; Hypolipidemic Agents; Lipolysis; Male; Middle Aged; Norepinephrine; Pyrazines | 1992 |
Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
Topics: 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glycerol; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Male; Middle Aged; Obesity; Pyrazines; Pyruvates; Triglycerides | 1992 |
Acipimox-induced facial skin flush: frequency, thermographic evaluation and relationship to plasma acipimox level.
Topics: Adult; Dose-Response Relationship, Drug; Female; Flushing; Humans; Hypolipidemic Agents; Male; Pyrazines; Reproducibility of Results; Thermography; Time Factors | 1992 |
Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Energy Metabolism; Female; Glucose; Glucose Clamp Technique; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Pyrazines; Time Factors | 1992 |
A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
Topics: Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipids; Male; Middle Aged; Pyrazines; Triglycerides | 1992 |
Plasma free fatty acids and serum insulin in subjects feeding at 12-hour intervals; effects of methionyl growth hormone and of acipimox, an inhibitor of lipolysis.
Topics: Circadian Rhythm; Double-Blind Method; Fatty Acids, Nonesterified; Food; Glycerol; Growth Hormone; Hormones; Human Growth Hormone; Humans; Insulin; Lipolysis; Male; Pyrazines | 1992 |
A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
Topics: Adult; Aged; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pyrazines | 1992 |
Effect of acute inhibition of lipolysis on operation of the glucose-fatty acid cycle in hepatic cirrhosis.
Topics: 3-Hydroxybutyric Acid; Aged; Blood Glucose; Fatty Acids; Fatty Acids, Nonesterified; Glucose Tolerance Test; Glycerol; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin Resistance; Lipolysis; Liver Cirrhosis; Male; Middle Aged; Pyrazines; Reference Values | 1992 |
Role of plasma non-esterified fatty acids during and after exercise.
Topics: Adult; Carbohydrate Metabolism; Fatty Acids, Nonesterified; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Oxidation-Reduction; Physical Exertion; Pyrazines | 1991 |
Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin.
Topics: Adult; Fatty Acids, Nonesterified; Feedback; Growth Hormone; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypothalamus; Lipolysis; Male; Pyrazines; Pyridostigmine Bromide; Somatostatin | 1991 |
[Personal experience with the hypolipidemic agent Olbetam-Acipimox in hyperlipoproteinemia associated with type II diabetes].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrazines | 1991 |
A comparison between nicotinic acid and acipimox in hypertriglyceridaemia--effects on serum lipids, lipoproteins, glucose tolerance and tolerability.
Topics: Adult; Blood Glucose; Female; Glucose Tolerance Test; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pyrazines | 1991 |
Acipimox stimulates skin blood flow by a cyclo-oxygenase-dependent mechanism.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Cyclooxygenase Inhibitors; Female; Hemodynamics; Humans; Hypolipidemic Agents; Male; Pyrazines; Regional Blood Flow; Skin; Skin Temperature | 1990 |
Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects.
Topics: Adult; Blood Glucose; Fatty Acids, Nonesterified; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Insulin; Lipolysis; Male; Pyrazines | 1990 |
Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Double-Blind Method; Drug Therapy, Combination; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoproteins; Patient Compliance; Pyrazines; Triglycerides | 1990 |
Effects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination.
Topics: Adult; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Feces; Female; Humans; Hypolipidemic Agents; Intestinal Absorption; Lipids; Lipoproteins; Male; Phenotype; Pyrazines; Squalene; Sterols | 1989 |
Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia.
Topics: Adult; Cholesterol, HDL; Clinical Trials as Topic; Double-Blind Method; Humans; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Lipase; Lipoprotein Lipase; Lipoproteins, HDL; Male; Middle Aged; Phospholipids; Pyrazines; Random Allocation; Triglycerides | 1988 |
Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.
Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrazines; Triglycerides | 1988 |
Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug.
Topics: Adult; Cholestyramine Resin; Clinical Trials as Topic; Drug Interactions; Humans; Hypolipidemic Agents; Kinetics; Pyrazines; Random Allocation | 1986 |
Acipimox in the treatment of patients with hyperlipidaemia: a double blind trial.
Topics: Adult; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Random Allocation; Triglycerides | 1986 |
A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins A; Apolipoproteins B; Cholesterol; Clofibrate; Female; Humans; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipase; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Pyrazines; Triglycerides | 1985 |
Effects of Acipimox on plasma lipids and biliary lipids in healthy subjects.
Topics: Adult; Bile; Humans; Lipid Metabolism; Lipids; Lipoproteins; Male; Patient Compliance; Pyrazines | 1985 |
[Acipimox treatment of hyperlipidemia type II].
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Placebos; Pyrazines | 1982 |
Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent.
Topics: Administration, Oral; Adult; Biological Availability; Clinical Trials as Topic; Fasting; Humans; Hypolipidemic Agents; Kinetics; Male; Pyrazines; Random Allocation | 1981 |
Acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid levels in hyperthyroidism.
Topics: Administration, Oral; Adult; Fatty Acids, Nonesterified; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hyperthyroidism; Hypolipidemic Agents; Male; Pyrazines | 1995 |
Effect of lipid-lowering treatment on progression of atherosclerotic lesions--a duplex ultrasonographic investigation.
Topics: Arteriosclerosis; Cholesterol, LDL; Combined Modality Therapy; Female; Humans; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrazines; Ultrasonography | 1995 |
Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients. Role of free fatty acid and insulin levels.
Topics: Adult; Biological Transport, Active; Deoxyglucose; Diabetes Mellitus, Type 1; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Fluorodeoxyglucose F18; Glucose; Glucose Clamp Technique; Humans; Hypolipidemic Agents; Insulin; Male; Myocardium; Pyrazines; Somatostatin; Tomography, Emission-Computed | 1995 |
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides | 1995 |
Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans.
Topics: Adult; Blood Glucose; Fasting; Fatty Acids, Nonesterified; Glucose; Humans; Hypolipidemic Agents; Insulin; Lipolysis; Male; Muscle, Skeletal; Myocardium; Pyrazines | 1994 |
Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects.
Topics: Administration, Oral; Adult; Blood Glucose; Body Mass Index; Circadian Rhythm; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glycerol; Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Insulin-Like Growth Factor I; Lipolysis; Male; Middle Aged; Obesity; Pulsatile Flow; Pyrazines | 1994 |
The effect of an antilipolytic agent (acipimox) on the insulin resistance of lipid and glucose metabolism in hypertriglyceridaemic patients.
Topics: Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Lipolysis; Male; Middle Aged; Oxidation-Reduction; Palmitates; Pyrazines | 1994 |
Availability of glucose ingested during muscle exercise performed under acipimox-induced lipolysis blockade.
Topics: Administration, Oral; Adult; Blood Glucose; C-Peptide; Calorimetry, Indirect; Carbohydrate Metabolism; Energy Metabolism; Glucagon; Glucose; Glycerol; Humans; Hypolipidemic Agents; Insulin; Lipid Metabolism; Lipolysis; Male; Oxidation-Reduction; Physical Exertion; Pyrazines | 1994 |
Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
Topics: Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypolipidemic Agents; Insulin; Lactates; Lactic Acid; Male; Middle Aged; Osmolar Concentration; Placebos; Pyrazines; Time Factors | 1994 |
The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Niacin; Pyrazines; Triglycerides | 1993 |
Lipoprotein structure in male subjects during in vivo lipolysis: effect of an anti-lipolytic treatment with acipimox.
Topics: Adult; Double-Blind Method; Epinephrine; Fats; Humans; Hypolipidemic Agents; Lipids; Lipolysis; Lipoproteins; Male; Pyrazines | 1993 |
Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM.
Topics: Analysis of Variance; Blood Glucose; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucagon; Gluconeogenesis; Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Lactates; Lipolysis; Liver; Male; Middle Aged; Oxygen Consumption; Pyrazines; Tritium | 1993 |
Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Insulin; Lipids; Lipoproteins; Male; Middle Aged; Pyrazines; Triglycerides | 1993 |
Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
Topics: Blood Glucose; Calorimetry; Chromatography, High Pressure Liquid; Circadian Rhythm; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycerol; Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin; Liver; Male; Middle Aged; Pyrazines; Time Factors | 1993 |
Suppression of lipolysis in normal man does not inhibit recovery from insulin-induced hypoglycaemia.
Topics: Acetoacetates; Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Glycerol; Humans; Hyperlipidemias; Hypoglycemia; Hypolipidemic Agents; Insulin; Lipolysis; Male; Pyrazines | 1993 |
The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; C-Peptide; Calorimetry; Carbon Dioxide; Diabetes Mellitus, Type 2; Energy Metabolism; Exercise; Fatty Acids, Nonesterified; Female; Glucagon; Glycerol; Growth Hormone; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Male; Middle Aged; Nitrogen; Oxygen Consumption; Pyrazines; Reference Values | 1993 |
Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
Topics: Adult; Alanine; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucagon; Glucose; Glycerol; Growth Hormone; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Lipid Metabolism; Male; Oxidation-Reduction; Pyrazines; Pyruvates; Radioimmunoassay; Time Factors | 1993 |
The effects of changes in plasma nonesterified fatty acid levels on oxidative metabolism during moderate exercise in patients with non-insulin-dependent diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Blood Glucose; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Exercise; Fatty Acids, Nonesterified; Glycerol; Growth Hormone; Heparin; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Ketone Bodies; Male; Middle Aged; Norepinephrine; Pyrazines; Triglycerides | 1993 |
Peripheral and hepatic insulin sensitivity in non-insulin-dependent diabetes mellitus: effect of nonesterified fatty acids.
Topics: Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Forearm; Glucose; Hormones; Humans; Hypolipidemic Agents; Insulin; Liver; Male; Middle Aged; Osmolar Concentration; Pyrazines | 1993 |
The impact of a short course of three lipid lowering drugs on fat oxidation during exercise in healthy volunteers.
Topics: Adult; Anticholesteremic Agents; Blood Pressure; Energy Metabolism; Exercise; Exercise Test; Exercise Tolerance; Fatty Acids, Nonesterified; Gemfibrozil; Heart Rate; Humans; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Lovastatin; Male; Oxidation-Reduction; Oxygen Consumption; Pyrazines; Random Allocation; Simvastatin; Single-Blind Method | 1993 |
Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
Topics: Adult; Fatty Acids, Nonesterified; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Male; Obesity; Pyrazines | 1996 |
Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Forearm; Glucose; Glucose Tolerance Test; Glycerol; Glycogen; Humans; Hydroxybutyrates; Hypolipidemic Agents; Kinetics; Middle Aged; Muscle, Skeletal; Pyrazines; Regional Blood Flow; Thinness; Time Factors | 1996 |
Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
Topics: Adolescent; Adult; Drug Synergism; Fatty Acids, Nonesterified; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Male; Oligopeptides; Pyrazines; Pyridostigmine Bromide; Reference Values | 1996 |
Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Topics: Adolescent; Adult; Fatty Acids, Nonesterified; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Male; Middle Aged; Obesity; Oligopeptides; Pyrazines; Pyridostigmine Bromide | 1996 |
Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Topics: Adult; Aged; Aging; Blood Glucose; Cross-Over Studies; Fatty Acids, Nonesterified; Female; Gonadotropin-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Lipolysis; Male; Obesity; Pyrazines; Single-Blind Method | 1996 |
Role of fat-derived substrates in the regulation of gluconeogenesis during fasting.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Adult; Fasting; Fatty Acids, Nonesterified; Female; Gluconeogenesis; Humans; Hydroxybutyrates; Hypolipidemic Agents; Ketone Bodies; Male; Pyrazines | 1996 |
Inhibition of lipolysis stimulates whole body glucose production and disposal in normal postabsorptive subjects.
Topics: Adult; Blood Glucose; Calorimetry, Indirect; Fasting; Female; Glucose; Hormones; Humans; Hypolipidemic Agents; Lipolysis; Male; Nitrogen; Osmolar Concentration; Pyrazines; Time Factors | 1997 |
The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Topics: Adult; Aged; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pyrazines; Simvastatin; Treatment Outcome; Triglycerides | 1997 |
Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrazines | 1997 |
Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects.
Topics: Adult; Cross-Over Studies; Fatty Acids, Nonesterified; Female; Glycerol; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Insulin; Male; Pyrazines; Single-Blind Method; Time Factors | 1997 |
Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Triglycerides | 1997 |
Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome.
Topics: Adult; Cushing Syndrome; Fatty Acids, Nonesterified; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Middle Aged; Pyrazines | 1997 |
Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
Topics: Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Cholesterol; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin; Male; Placebos; Pyrazines; Triglycerides | 1998 |
Can acipimox reduce serum lipoprotein(a) levels in hemodialyzed patients?
Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Pyrazines; Renal Dialysis | 1998 |
Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects.
Topics: Adult; Apolipoproteins; Apolipoproteins B; Blood Glucose; Humans; Hypolipidemic Agents; Insulin; Lipids; Lipolysis; Lipoproteins, VLDL; Male; Pyrazines; Reference Values | 1998 |
The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines; Simvastatin; Treatment Outcome | 1998 |
Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
Topics: Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Oxygen Consumption; Placebos; Pyrazines | 1998 |
Acute changes in free-fatty acids (FFA) do not alter serum leptin levels.
Topics: Adult; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Heparin; Humans; Hypolipidemic Agents; Kinetics; Leptin; Male; Obesity; Placebos; Proteins; Pyrazines | 1998 |
Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pyrazines | 1998 |
Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.
Topics: Blood Viscosity; Cell Aggregation; Cross-Over Studies; Double-Blind Method; Female; Hemorheology; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines | 1998 |
Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
Topics: Adult; Fatty Acids, Nonesterified; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Male; Middle Aged; Obesity; Pyrazines | 1998 |
Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia.
Topics: Adult; Aged; Cholesterol, VLDL; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Safety; Simvastatin | 1998 |
The reduction in postprandial lipemia after exercise is independent of the relative contributions of fat and carbohydrate to energy metabolism during exercise.
Topics: Adult; Blood Glucose; Body Mass Index; Carbohydrate Metabolism; Catecholamines; Eating; Energy Metabolism; Exercise; Exercise Test; Fats; Fatty Acids, Nonesterified; Glycogen; Humans; Hypolipidemic Agents; Lactic Acid; Lipids; Male; Postprandial Period; Pyrazines; Triglycerides | 1999 |
The control on growth hormone release by free fatty acids is maintained in acromegaly.
Topics: Acromegaly; Adult; Aged; Fatty Acids, Nonesterified; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Male; Middle Aged; Pyrazines; Thyrotropin-Releasing Hormone | 1999 |
Intensive lipid-lowering strategy in patients with diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines; Simvastatin; Triglycerides | 1999 |
Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients.
Topics: Adult; Carrier Proteins; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Glycoproteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipids; Male; Membrane Proteins; Middle Aged; Phospholipid Transfer Proteins; Pyrazines; Reference Values; Time Factors | 1999 |
Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
Topics: Adult; Basal Metabolism; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Obesity; Oxidation-Reduction; Pyrazines | 1999 |
Combined hyperinsulinaemic glucose clamp and oral acipimox for optimizing metabolic conditions during 18F-fluorodeoxyglucose gated PET cardiac imaging: comparative results.
Topics: Administration, Oral; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fluorodeoxyglucose F18; Glucose Clamp Technique; Heart; Humans; Hyperinsulinism; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Pyrazines; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed | 1998 |
A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Double-Blind Method; Fatty Alcohols; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Treatment Outcome | 1999 |
Effects of free fatty acids and acipimox, a lipolysis inhibitor, on the somatotroph responsiveness to GHRH in anorexia nervosa.
Topics: Adolescent; Adult; Analysis of Variance; Anorexia Nervosa; Case-Control Studies; Fatty Acids, Nonesterified; Feedback; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Insulin-Like Growth Factor I; Lipids; Pyrazines; Statistics, Nonparametric | 2000 |
[Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Triglycerides | 2000 |
The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients.
Topics: Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Insulin; Leptin; Male; Middle Aged; Niacin; Pyrazines; Triglycerides | 2000 |
Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.
Topics: Aged; Area Under Curve; Blood Glucose; Fatty Acids, Nonesterified; Female; Growth Hormone-Releasing Hormone; Hormones; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 1; Male; Obesity; Oligopeptides; Pyrazines | 2000 |
Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients.
Topics: Acromegaly; Adenoma; Area Under Curve; Fatty Acids, Nonesterified; Feedback; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Male; Middle Aged; Niacin; Pituitary Neoplasms; Pyrazines; Statistics, Nonparametric | 2001 |
The role of free fatty acids (FFA) in the regulation of intrahepatic fluxes of glucose and glycogen metabolism during short-term starvation in healthy volunteers.
Topics: Cross-Over Studies; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids, Nonesterified; Food Deprivation; Gluconeogenesis; Glucose; Glycogen; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Pyrazines | 2001 |
Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Body Mass Index; C-Peptide; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Growth Hormone-Releasing Hormone; Hormones; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipids; Obesity; Polycystic Ovary Syndrome; Pyrazines | 2001 |
Effects of fatty acids on exercise plus insulin-induced glucose utilization in trained and sedentary subjects.
Topics: Adult; Bicycling; Blood Glucose; Calorimetry, Indirect; Carbohydrate Metabolism; Exercise; Fatty Acids; Fatty Acids, Nonesterified; Glucose; Humans; Hypolipidemic Agents; Insulin; Lactic Acid; Life Style; Lipid Metabolism; Lipids; Osmolar Concentration; Oxidation-Reduction; Physical Education and Training; Physical Endurance; Pyrazines; Reference Values | 2002 |
Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
Topics: Adult; Blood Glucose; Double-Blind Method; Energy Metabolism; Fatty Acids, Nonesterified; Female; Glucose; Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Oxidation-Reduction; Pyrazines | 2001 |
A pilot study of the long-term effects of acipimox in polycystic ovarian syndrome.
Topics: Adult; Blood Glucose; C-Peptide; Female; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Insulin; Obesity; Pilot Projects; Polycystic Ovary Syndrome; Pyrazines; Thinness; Time Factors; Triglycerides | 2002 |
The effect of long-term pharmacological antilipolysis on substrate metabolism in growth hormone (GH)-substituted GH-deficient adults.
Topics: Adult; Body Composition; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Growth Hormone; Hormones; Human Growth Hormone; Humans; Hypolipidemic Agents; Lipoprotein Lipase; Lipoproteins; Male; Metabolism, Inborn Errors; Middle Aged; Phenylalanine; Pyrazines; Tyrosine | 2002 |
Effects of lowering circulating free fatty acid levels on protein metabolism in adult growth hormone deficient patients.
Topics: Adult; Area Under Curve; Blood Glucose; Dwarfism, Pituitary; Fatty Acids, Nonesterified; Female; Forearm; Growth Hormone; Humans; Hypolipidemic Agents; Lipolysis; Male; Middle Aged; Phenylalanine; Proteins; Pyrazines; Tyrosine; Urea | 2002 |
Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution.
Topics: Adipose Tissue; Adult; Area Under Curve; Fasting; Fatty Acids; Glucose Tolerance Test; HIV Infections; Humans; Hyperinsulinism; Hypolipidemic Agents; Insulin Resistance; Lipodystrophy; Lipolysis; Male; Middle Aged; Protease Inhibitors; Pyrazines; Viscera | 2003 |
Feasibility and image quality of dual-isotope SPECT using 18F-FDG and (99m)Tc-tetrofosmin after acipimox administration.
Topics: Administration, Oral; Chronic Disease; Coronary Artery Disease; Echocardiography; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heart; Humans; Male; Middle Aged; Organophosphorus Compounds; Organotechnetium Compounds; Pyrazines; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Ventricular Dysfunction, Left | 2003 |
Diagnosis of growth hormone deficiency after pituitary surgery: the combined acipimox/GH-releasing hormone test.
Topics: Adenoma; Adolescent; Adult; Aged; Area Under Curve; Arginine; Fatty Acids, Nonesterified; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Insulin; Male; Middle Aged; Pituitary Neoplasms; Predictive Value of Tests; Pyrazines; Stimulation, Chemical | 2003 |
Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability.
Topics: Blood Glucose; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heart Ventricles; Humans; Male; Middle Aged; Pyrazines; Radionuclide Imaging; Radiopharmaceuticals; Ventricular Dysfunction, Left | 2003 |
Effect of beta1- and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans.
Topics: Adult; Albuterol; Carrier Proteins; Dobutamine; Dose-Response Relationship, Drug; Energy Metabolism; Fats; Fatty Acids, Nonesterified; Glucose; Humans; Ion Channels; Male; Mitochondrial Proteins; Muscle, Skeletal; Oxygen Consumption; Pyrazines; Receptors, Adrenergic, beta; Thigh; Uncoupling Protein 3 | 2003 |
Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
Topics: Adult; Body Mass Index; Evaluation Studies as Topic; Female; Glucose Tolerance Test; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Insulin; Male; Middle Aged; Obesity; Oligopeptides; Pyrazines | 2003 |
The decisive role of free fatty acids for protein conservation during fasting in humans with and without growth hormone.
Topics: Adult; Amino Acids; Fasting; Fatty Acids, Nonesterified; Growth Hormone; Heparin; Hormone Antagonists; Human Growth Hormone; Humans; Hypolipidemic Agents; Lipolysis; Male; Microdialysis; Muscle, Skeletal; Phenylalanine; Proteins; Pyrazines; Somatostatin; Triglycerides; Tyrosine; Urea | 2003 |
Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy.
Topics: Adult; Algorithms; Case-Control Studies; Fatty Acids, Nonesterified; Ghrelin; HIV-Associated Lipodystrophy Syndrome; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin-Like Growth Factor I; Male; Peptide Hormones; Pyrazines; Somatostatin | 2004 |
Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Double-Blind Method; Energy Metabolism; Fatty Acids, Nonesterified; Female; Hormone Replacement Therapy; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Lipolysis; Male; Middle Aged; Pyrazines | 2003 |
Acipimox enhances spontaneous growth hormone secretion in obese women.
Topics: Adipose Tissue; Adult; Body Composition; Entropy; Fatty Acids, Nonesterified; Female; Half-Life; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin-Like Growth Factor I; Obesity; Pyrazines | 2004 |
Acute regulation of adiponectin by free fatty acids.
Topics: Adiponectin; Adult; Blood Glucose; Fasting; Fatty Acids, Nonesterified; Humans; Hypolipidemic Agents; Insulin; Intercellular Signaling Peptides and Proteins; Longitudinal Studies; Male; Middle Aged; Proteins; Pyrazines | 2004 |
FFAs are not involved in regulation of gluconeogenesis and glycogenolysis in adults with uncomplicated P. falciparum malaria.
Topics: Adult; Alanine; Fatty Acids, Nonesterified; Female; Gluconeogenesis; Glucose; Glycogen; Humans; Hypolipidemic Agents; Insulin; Interleukin-10; Lactic Acid; Malaria, Falciparum; Male; Pyrazines; Tumor Necrosis Factor-alpha | 2004 |
Free fatty acids increase hepatic glycogen content in obese males.
Topics: Adult; C-Peptide; Fasting; Fatty Acids, Nonesterified; Gas Chromatography-Mass Spectrometry; Gluconeogenesis; Glucose; Hormones; Humans; Hypolipidemic Agents; Insulin; Liver Glycogen; Male; Middle Aged; Obesity; Pyrazines; Stimulation, Chemical | 2004 |
Enhanced circadian ACTH release in obese premenopausal women: reversal by short-term acipimox treatment.
Topics: Adrenocorticotropic Hormone; Adult; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Down-Regulation; Fatty Acids, Nonesterified; Female; Follicular Phase; Humans; Hydrocortisone; Hypolipidemic Agents; Hypothalamo-Hypophyseal System; Obesity; Pituitary-Adrenal System; Premenopause; Pyrazines; Reference Values; Statistics, Nonparametric | 2004 |
The effects of exercise and adipose tissue lipolysis on plasma adiponectin concentration and adiponectin receptor expression in human skeletal muscle.
Topics: Adiponectin; Adipose Tissue; Adult; Arterioles; Calorimetry, Indirect; Exercise; Fasting; Fatty Acids, Nonesterified; Humans; Hypolipidemic Agents; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Lipolysis; Male; Muscle Fibers, Skeletal; Muscle, Skeletal; Osmolar Concentration; Pyrazines; Receptors, Adiponectin; Receptors, Cell Surface; RNA, Messenger; Sarcolemma | 2005 |
Inhibition of adipose tissue lipolysis increases intramuscular lipid use in type 2 diabetic patients.
Topics: Adipose Tissue; Aged; Algorithms; Body Composition; Body Mass Index; Breath Tests; Diabetes Mellitus, Type 2; Diet; Energy Metabolism; Exercise Test; Fatty Acids, Nonesterified; Female; Glycogen; Humans; Hypolipidemic Agents; Insulin; Kinetics; Lipolysis; Male; Middle Aged; Muscle, Skeletal; Oxidation-Reduction; Palmitates; Pyrazines | 2005 |
Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis.
Topics: Adult; Drug Combinations; Fasting; Fatty Acids, Nonesterified; Female; Ghrelin; Growth Hormone; Hormone Replacement Therapy; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin Resistance; Leptin; Lipolysis; Male; Middle Aged; Peptide Hormones; Pyrazines; Steroid Metabolism, Inborn Errors; Sterol Esterase | 2005 |
Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Topics: Acyl Coenzyme A; Adiponectin; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin; Male; Middle Aged; Muscle, Skeletal; Pyrazines | 2005 |
Free fatty acids decrease circulating ghrelin concentrations in humans.
Topics: Adult; Anticoagulants; Blood Glucose; C-Peptide; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Ghrelin; Glucose Clamp Technique; Heparin; Human Growth Hormone; Humans; Hydrocortisone; Hyperinsulinism; Hypolipidemic Agents; Insulin; Male; Peptide Hormones; Pyrazines; Somatostatin | 2006 |
Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.
Topics: Adult; Body Composition; Double-Blind Method; Fatty Acids, Nonesterified; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Placebos; Pyrazines; Triglycerides | 2006 |
[Effects of atorvastatin and acipimox on the lipid spectrum of blood plasma, endothelial function and a clinical course of unstable angina pectoris].
Topics: Angina, Unstable; Atorvastatin; Brachial Artery; Cholesterol, LDL; Drug Therapy, Combination; Endothelium, Vascular; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pyrazines; Pyrroles; Treatment Outcome; Vasodilation | 2006 |
Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure.
Topics: Aged; Cardiac Output, Low; Cardiomyopathy, Dilated; Coronary Circulation; Echocardiography; Fatty Acids, Nonesterified; Female; Heart; Heart Rate; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardium; Oxidation-Reduction; Positron-Emission Tomography; Pyrazines; Ventricular Function, Left | 2006 |
Reduced plasma free fatty acid availability during exercise: effect on gene expression.
Topics: Administration, Oral; Animals; Carnitine O-Palmitoyltransferase; Cell Line; Cross-Over Studies; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Gene Expression; Glycerol; Heat-Shock Proteins; Humans; Hypolipidemic Agents; Ion Channels; Lipid Metabolism; Male; Mitochondrial Proteins; Muscle Fibers, Skeletal; Muscle, Skeletal; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Physical Endurance; Protein Kinases; Pyrazines; Rats; RNA-Binding Proteins; RNA, Messenger; Time Factors; Transcription Factors; Uncoupling Protein 3 | 2007 |
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Genetic Predisposition to Disease; Glucose Clamp Technique; Hormones; Humans; Hyperglycemia; Hypolipidemic Agents; Insulin; Insulin Secretion; Male; Osmolar Concentration; Pyrazines; Time Factors | 2007 |
Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free fatty acid concentration.
Topics: Adult; Fatty Acids, Nonesterified; Female; Free Radical Scavengers; Gene Expression Profiling; Gene Expression Regulation; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Muscle Proteins; Muscle, Skeletal; Pyrazines; RNA, Messenger | 2007 |
Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy.
Topics: Biopsy; Fatty Acids, Nonesterified; Glucose; Glycogen Synthase; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin; Lipolysis; Male; Middle Aged; Palmitates; Pyrazines; Signal Transduction | 2007 |
Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects.
Topics: Adult; Fasting; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Human Growth Hormone; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Lipolysis; Male; Pyrazines; Young Adult | 2009 |
Effects of growth hormone and free fatty acids on insulin sensitivity in patients with type 1 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Fatty Acids, Nonesterified; Female; Human Growth Hormone; Humans; Insulin Resistance; Male; Pyrazines | 2009 |
The assessment of human regional drug absorption of free acid and sodium salt forms of acipimox, in healthy volunteers, to direct modified release formulation strategy.
Topics: Adult; Biological Availability; Colon; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Hypolipidemic Agents; Intestine, Small; Male; Middle Aged; Permeability; Pyrazines; Salts; Solubility; Young Adult | 2009 |
Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Chronic Disease; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fatty Acids, Nonesterified; Female; Heart; Heart Failure; Humans; Hypolipidemic Agents; Male; Metabolism; Middle Aged; Pyrazines; Stroke Volume; Vascular Resistance | 2010 |
Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome.
Topics: Administration, Oral; Adult; Algorithms; Cells, Cultured; Down-Regulation; Female; Humans; Hypolipidemic Agents; Inflammation; Insulin; Male; Metabolic Syndrome; Middle Aged; Neutrophils; Pyrazines; Time Factors | 2011 |
Contribution of nonesterified fatty acids to mitogen-activated protein kinase activation in human skeletal muscle during endurance exercise.
Topics: Diabetes Mellitus; Exercise; Fatty Acids, Nonesterified; Humans; Hypolipidemic Agents; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Middle Aged; Muscle, Skeletal; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Physical Endurance; Pyrazines; Sedentary Behavior; Young Adult | 2013 |
Short-term exercise combined with Acipimox administration induces an increase in plasma ACTH and its subsequent fall in the recovery phase in bulimic women.
Topics: Adrenocorticotropic Hormone; Adult; Bulimia; Exercise; Female; Humans; Pyrazines; Single-Blind Method | 2013 |
Pharmacokinetics and bioequivalence evaluation of two acipimox tablets: a single-dose, randomized-sequence, two-way crossover study in healthy Chinese male volunteers.
Topics: Adult; Chemistry, Pharmaceutical; Cross-Over Studies; Humans; Male; Pyrazines; Tablets; Therapeutic Equivalency | 2013 |
Acute reduction of lipolysis reduces adiponectin and IL-18: evidence from an intervention study with acipimox and insulin.
Topics: Adiponectin; Cross-Over Studies; Female; Humans; Insulin; Interleukin-18; Lipodystrophy; Lipolysis; Male; Middle Aged; Pyrazines | 2013 |
Kinetics and utilization of lipid sources during acute exercise and acipimox.
Topics: Adult; Exercise; Humans; Hypolipidemic Agents; Lipolysis; Lipoproteins, VLDL; Male; Middle Aged; Muscle, Skeletal; Overweight; Palmitic Acid; Pyrazines; Triglycerides; Young Adult | 2014 |
Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans.
Topics: Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Pyrazines | 2015 |
Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
Topics: Adult; Blood Glucose; Body Composition; Down-Regulation; Energy Metabolism; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Obesity; Pyrazines; Young Adult | 2016 |
Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glucose Tolerance Test; Glucosides; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Pyrazines; Young Adult | 2016 |
Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes.
Topics: Adipose Tissue; Aged; Austria; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Down-Regulation; Energy Metabolism; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Lipolysis; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Proton Magnetic Resonance Spectroscopy; Pyrazines; Risk Factors; Single-Blind Method; Stroke Volume; Systole; Time Factors; Treatment Outcome; Ventricular Function, Left | 2016 |
Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Cross-Over Studies; Denmark; Double-Blind Method; Fatty Acids, Nonesterified; Heart; Heart Rate; Humans; Hypolipidemic Agents; Hypopituitarism; Insulin; Lipolysis; Male; Parasympathetic Nervous System; Pyrazines; Time Factors; Treatment Outcome | 2017 |
Adipose tissue lipolytic inhibition enhances the glucoregulatory properties of exercise in type 2 diabetes patients.
Topics: Adipose Tissue; Administration, Oral; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Fatty Acids; Glycogen; Humans; Hypolipidemic Agents; Insulin; Lactic Acid; Lipid Metabolism; Male; Middle Aged; Pyrazines; Triglycerides | 2018 |
Effects of 3-hydroxybutyrate and free fatty acids on muscle protein kinetics and signaling during LPS-induced inflammation in humans: anticatabolic impact of ketone bodies.
Topics: 3-Hydroxybutyric Acid; Adult; Biomarkers; Blotting, Western; Fatty Acids, Nonesterified; Glucose Clamp Technique; Humans; Hypolipidemic Agents; Inflammation; Insulin Resistance; Ketone Bodies; Kinetics; Lipopolysaccharides; Male; Muscle Proteins; Muscle, Skeletal; Phosphorylation; Protein Biosynthesis; Proteolysis; Pyrazines; Ribosomal Protein S6 Kinases; Signal Transduction; Young Adult | 2018 |
Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.
Topics: Adult; Animals; Blood Glucose; Cells, Cultured; Cross-Over Studies; Enteroendocrine Cells; Fatty Acids, Nonesterified; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Hypopituitarism; Insulin Resistance; Intestinal Mucosa; Lipolysis; Male; Middle Aged; Overweight; Pilot Projects; Primary Cell Culture; Pyrazines; Rats | 2019 |
Impact of Acipimox Therapy on Free Fatty Acid Efflux and Endothelial Function in the Metabolic Syndrome: A Randomized Trial.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Pyrazines; Vasodilation | 2019 |
Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals.
Topics: Calorimetry, Indirect; Ceramides; Diglycerides; Electrophoresis, Capillary; Growth Hormone; Humans; Insulin Resistance; Lipid Metabolism; Lipolysis; Male; Muscle, Skeletal; Polymerase Chain Reaction; Pyrazines; Pyruvate Dehydrogenase Complex | 2020 |
Investigation of the clinical effects of acipimox in patients with vulnerable carotid atherosclerosis.
Topics: Carotid Arteries; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Humans; Lipids; Pyrazines | 2023 |
Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy.
Topics: Adenosine Triphosphate; Adult; Aspirin; Child; Fatigue; Humans; Mitochondrial Myopathies; Muscular Diseases; Pyrazines; Quality of Life; Randomized Controlled Trials as Topic | 2022 |
114 other study(ies) available for pyrazines and acipimox
| Article | Year |
|---|---|
Lack of acipimox-digoxin interaction in patient volunteers.
Topics: Aged; Aged, 80 and over; Digoxin; Drug Interactions; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrazines | 1992 |
Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia: effect of acipimox therapy.
Topics: Adult; Aged; Aged, 80 and over; Apolipoproteins B; Cholesterol, HDL; Cholesterol, VLDL; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Phenotype; Pyrazines; Triglycerides | 1992 |
Resolution of nicotinic acid-induced acanthosis nigricans by substitution of an analogue (acipimox) in a patient with type V hyperlipidaemia.
Topics: Acanthosis Nigricans; Adult; Axilla; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Nicotinic Acids; Pyrazines | 1992 |
Reversal of steroid-induced insulin resistance by a nicotinic-acid derivative in man.
Topics: Adrenal Cortex Hormones; Adult; Energy Metabolism; Fatty Acids, Nonesterified; Glucose; Humans; Hypolipidemic Agents; Insulin Resistance; Middle Aged; Pyrazines | 1992 |
Effects of cholestyramine and acipimox on subfractions of plasma low density lipoprotein. Studies in normolipidaemic and hypercholesterolaemic subjects.
Topics: Adult; Centrifugation, Density Gradient; Cholestyramine Resin; Drug Therapy, Combination; Electrophoresis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Reference Values | 1992 |
[Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia].
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Complications; Humans; Hyperlipidemias; Hypolipidemic Agents; Pantetheine; Pyrazines; Risk Factors | 1991 |
[Acipimox in primary hyperlipidemias: safety and efficacy evaluated in six months].
Topics: Adolescent; Adult; Aged; Cholesterol; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Triglycerides | 1991 |
Modulation of hepatic glucose production by non-esterified fatty acids in type 2 (non-insulin-dependent) diabetes mellitus.
Topics: Administration, Oral; Adult; Biological Transport; Calorimetry; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Heparin; Humans; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Lipid Metabolism; Liver; Middle Aged; Oxidation-Reduction; Palmitates; Pyrazines | 1991 |
Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Topics: Biological Transport; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Glycogen Synthase; Humans; Hypolipidemic Agents; Lactates; Lactic Acid; Lipid Metabolism; Middle Aged; Muscles; Oxidation-Reduction; Pyrazines; Pyruvate Dehydrogenase Complex | 1991 |
Increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia.
Topics: Adult; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Receptors, LDL | 1991 |
Biliary lipids in familial combined hyperlipidaemia: effects of acipimox therapy.
Topics: Adult; Aged; Bile; Cholelithiasis; Cholesterol; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Pyrazines | 1990 |
Lipoprotein changes and increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia.
Topics: Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Pyrazines; Receptors, LDL | 1990 |
Acipimox and hypertriglyceridaemia.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Pyrazines | 1990 |
The effect of Acipimox on triacylglycerol metabolism in rat.
Topics: Acyltransferases; Animals; Diacylglycerol O-Acyltransferase; Fatty Acids, Nonesterified; Hypolipidemic Agents; Kinetics; Liver; Male; Phosphate Acetyltransferase; Phosphatidate Phosphatase; Pyrazines; Rats; Rats, Inbred Strains; Triglycerides | 1990 |
Safety, tolerability and efficacy of acipimox in type II hyperlipidaemia.
Topics: Cholesterol; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines | 1990 |
Treatment of hyperlipidaemia with acipimox.
Topics: Adult; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Pyrazines | 1989 |
Blood and plasma viscosity after acipimox treatment in hypertriglyceridemic patients.
Topics: Adolescent; Adult; Blood Viscosity; Cholesterol; Female; Humans; Hypertriglyceridemia; Lipids; Male; Middle Aged; Pyrazines; Triglycerides | 1988 |
Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa.
Topics: Adipose Tissue; Cholesterol; Fatty Acids; Glycerol; Humans; Hypolipidemic Agents; In Vitro Techniques; Intestinal Mucosa; Isoproterenol; Jejunum; Lipolysis; Pyrazines | 1985 |
Effects of antilipolytic agents on rat liver peroxisomes and peroxisomal oxidative activities.
Topics: Animals; Autophagy; Fatty Acids; Hypolipidemic Agents; Lipolysis; Liver; Male; Microbodies; Oxidation-Reduction; Pyrazines; Pyrazoles; Rats; Rats, Inbred Strains | 1985 |
A pilot study of the pharmacokinetics and triglyceride lowering activity of acipimox in dialyzed uremic patients.
Topics: Adult; Aged; Female; Humans; Hypolipidemic Agents; Kinetics; Male; Middle Aged; Pilot Projects; Pyrazines; Renal Dialysis; Time Factors; Triglycerides; Uremia | 1985 |
[Treatment of primary hyperlipidemia with 5-methylpyrazinecarboxylic acid (acipimox)].
Topics: Adolescent; Adult; Aged; Cholesterol; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Triglycerides | 1985 |
Effect of the antilipolytic compound acipimox on peroxisome marker enzymes, lipid pattern and biotransformation related functions in rat liver.
Topics: Animals; Biotransformation; Clofibrate; Cytochrome P-450 Enzyme System; Enzymes; Glutathione; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Microbodies; Molecular Weight; Proteins; Pyrazines; Rats | 1985 |
Inhibition of adenylate cyclase and stimulation of a high affinity GTPase by the antilipolytic agents, nicotinic acid, acipimox and various related compounds.
Topics: Adenylyl Cyclase Inhibitors; Adipose Tissue; Animals; Cricetinae; Epididymis; GTP Phosphohydrolases; Hypolipidemic Agents; In Vitro Techniques; Male; Niacin; Phosphoric Monoester Hydrolases; Pyrazines | 1983 |
Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) I - Mechanism of action.
Topics: Adipose Tissue; Animals; Bucladesine; Fatty Acids, Nonesterified; Lipolysis; Male; Nicotinic Acids; Norepinephrine; Oxidative Phosphorylation; Pyrazines; Rats; Theophylline | 1981 |
Radioimmunoassay of acipimox in human plasma and urine.
Topics: Animals; Cross Reactions; Humans; Hypolipidemic Agents; Male; Pyrazines; Rabbits; Radioimmunoassay | 1984 |
Effects of antilipolytic agents on peroxisomal beta-oxidation of fatty acids in rat liver.
Topics: Animals; Fatty Acids; Lipolysis; Liver; Male; Microbodies; Oxidation-Reduction; Pyrazines; Pyrazoles; Rats; Rats, Inbred Strains | 1983 |
Pharmacological profile of a new antilipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) II - Antilipolytic and blood lipid lowering activity.
Topics: Aging; Animals; Blood Glucose; Cholesterol; Fatty Acids, Nonesterified; Hypolipidemic Agents; Lipids; Lipolysis; Liver; Mice; Nicotinic Acids; Pyrazines; Rats; Triglycerides | 1981 |
Inhibition of lipolysis by nicotinic acid and by acipimox.
Topics: Adult; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Humans; Hypolipidemic Agents; Lipolysis; Male; Nicotinic Acids; Pyrazines | 1980 |
Effects of phlorizin and acipimox on insulin resistance in STZ-diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Female; Hypolipidemic Agents; Insulin Resistance; Phlorhizin; Pyrazines; Rats; Rats, Sprague-Dawley; Streptozocin | 1995 |
Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
Topics: Adult; Cohort Studies; Drug Synergism; Fatty Acids, Nonesterified; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Kinetics; Male; Obesity; Pyrazines; Reference Values; Time Factors | 1995 |
[Improvement of insulin sensitivity associated with the prolonged use of Acipimox in ++a morbid obese patient].
Topics: Adult; Blood Glucose; Fatty Acids, Nonesterified; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Male; Obesity, Morbid; Pyrazines; Time Factors | 1994 |
[Successful treatment of eruptive xanthomatosis with the antilipemic agents acipimox].
Topics: Combined Modality Therapy; Diet, Fat-Restricted; Humans; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Skin; Xanthomatosis | 1995 |
[Assessment of hypolipemic action of the preparation olbetam in people with primary hypercholesterolemia].
Topics: Adult; Aged; Cholesterol; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrazines | 1994 |
[Comparison of the effects of omega-3 polyunsaturated fatty acids and Olbetam (Acipimox) in the treatment of hypertriglyceridemia].
Topics: Fatty Acids, Omega-3; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrazines | 1994 |
Mechanisms of dexamethasone-induced insulin resistance in healthy humans.
Topics: Adult; Blood Glucose; Dexamethasone; Female; Glucose; Glucose Clamp Technique; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Leg; Male; Oxidation-Reduction; Pyrazines; Regional Blood Flow | 1994 |
Drug treatment of hypercholesterolaemia in a patient with Gilbert's syndrome.
Topics: Administration, Oral; Bezafibrate; Bilirubin; Colestipol; Gilbert Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Liver; Liver Function Tests; Lovastatin; Male; Middle Aged; Pravastatin; Pyrazines; Simvastatin | 1994 |
Lipid-lowering effect and safety of acipimox in hemodialysis patients and renal transplant recipients.
Topics: Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lipids; Male; Middle Aged; Pyrazines; Renal Dialysis; Uremia | 1994 |
Modification of myosin isozymes and SR Ca(2+)-pump ATPase of the diabetic rat heart by lipid-lowering interventions.
Topics: Animals; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Calcium-Transporting ATPases; Cyclopropanes; Diabetes Mellitus, Experimental; Epoxy Compounds; Heart; Heart Rate; Hypolipidemic Agents; Imidazoles; Male; Myosins; Propranolol; Pyrazines; Rats; Rats, Sprague-Dawley; Sarcoplasmic Reticulum | 1994 |
Normal splanchnic but impaired peripheral insulin-stimulated glucose uptake in cirrhosis.
Topics: Adult; Blood Glucose; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glucose Tolerance Test; Hepatic Veins; Humans; Hypolipidemic Agents; Indocyanine Green; Insulin; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Pyrazines; Somatostatin; Splanchnic Circulation | 1993 |
Modulation of the hypolipidemic effect of fish oil by inhibition of adipose tissue lipolysis with acipimox, a nicotinic acid analog.
Topics: Acetyl-CoA Carboxylase; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Dietary Fats, Unsaturated; Eating; Fatty Acids, Nonesterified; Fish Oils; Insulin; Lipids; Lipolysis; Liver; Male; Pyrazines; Rats; Rats, Wistar; Receptors, LDL; Sucrose; Triglycerides | 1993 |
Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative.
Topics: Adult; Aged; Coronary Angiography; Deoxyglucose; Diabetes Mellitus, Type 2; Echocardiography; Female; Fluorodeoxyglucose F18; Glucose; Glucose Clamp Technique; Heart; Humans; Male; Middle Aged; Myocardial Infarction; Myocardium; Nicotinic Acids; Pyrazines; Radionuclide Ventriculography; Tomography, Emission-Computed | 1994 |
[Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II].
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Treatment Outcome | 1993 |
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Brain; Cognition; Diabetes Mellitus, Type 1; Female; Glycerol; Homeostasis; Hormones; Humans; Hydroxybutyrates; Hypoglycemia; Hypolipidemic Agents; Insulin; Insulinoma; Ketone Bodies; Lactates; Lipolysis; Male; Pancreatic Neoplasms; Pyrazines; Reaction Time | 1993 |
Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Circadian Rhythm; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucose; Glucose Clamp Technique; Glycerol; Humans; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Lipids; Liver; Male; Middle Aged; Pyrazines; Time Factors; Triglycerides | 1993 |
Side effects of acipimox (Olbetam)
Topics: Contraindications; Humans; Hypolipidemic Agents; Pyrazines | 1993 |
Relationship between the size and phospholipid content of low-density lipoproteins.
Topics: Apolipoproteins B; Cholesterol; Electrophoresis, Polyacrylamide Gel; Humans; Hyperlipidemias; Lipoproteins, LDL; Molecular Weight; Phospholipids; Pyrazines; Triglycerides | 1993 |
[Pharma clinics. Drug of the month. Acipimox (Olbetam)].
Topics: Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Hypolipidemic Agents; Pyrazines | 1995 |
Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
Topics: Adult; Arginine; Fatty Acids, Nonesterified; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypolipidemic Agents; Obesity; Pyrazines | 1996 |
Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes.
Topics: Adenosine Deaminase; Adipocytes; Animals; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Glycerol; Hypolipidemic Agents; Isoproterenol; Kinetics; Lipase; Lipolysis; Male; Pyrazines; Rats; Rats, Wistar; Subcellular Fractions | 1996 |
[Effect of olbetam on hyperlipidemia in NIDDM].
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Triglycerides | 1995 |
Effects of Acipimox on the metabolism of free fatty acids and very low lipoprotein triglyceride.
Topics: Animals; Blood Glucose; Cholesterol, LDL; Cholesterol, VLDL; Eating; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycerol; Humans; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Lipoproteins, VLDL; Macaca mulatta; Male; Pyrazines; Reference Values; Triglycerides; Tritium | 1995 |
Effect of decreasing plasma free fatty acids by acipimox on hepatic glucose metabolism in normal rats.
Topics: Animals; Fatty Acids, Nonesterified; Gluconeogenesis; Glucose; Hypolipidemic Agents; Insulin; Liver; Liver Glycogen; Male; Pyrazines; Rats; Rats, Sprague-Dawley | 1996 |
Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols.
Topics: Aged; Blood Glucose; Coronary Disease; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose Clamp Technique; Glucose Tolerance Test; Heart; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Tomography, Emission-Computed, Single-Photon | 1997 |
Diagnostic pitfalls during therapy for extreme hypertriglyceridaemia.
Topics: Adult; Cholesterol, LDL; Combined Modality Therapy; Docosahexaenoic Acids; Eicosapentaenoic Acid; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Pyrazines; Triglycerides | 1997 |
Effect of acute acipimox administration on the rates of lipid and glycogen synthesis in cachectic tumor-bearing rats.
Topics: Animals; Blood Glucose; Cachexia; Gluconeogenesis; Glucose; Glycerol; Glycogen; Hypolipidemic Agents; Leydig Cell Tumor; Lipids; Lipolysis; Male; Pyrazines; Rats; Rats, Inbred F344; Testicular Neoplasms | 1997 |
Paradoxical high-density lipoprotein reduction induced by fibrate therapy.
Topics: Adult; Bezafibrate; Cholesterol, HDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrazines | 1997 |
Importance of catecholamines in defense against insulin hypoglycemia in humans.
Topics: Blood Glucose; Epinephrine; Fatty Acids, Nonesterified; Glucagon; Glucose; Glycerol; Heparin; Homeostasis; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypolipidemic Agents; Insulin; Lipolysis; Phentolamine; Propranolol; Pyrazines | 1998 |
Association of fasting plasma free fatty acid concentration and frequency of ventricular premature complexes in nonischemic non-insulin-dependent diabetic patients.
Topics: Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Logistic Models; Longitudinal Studies; Male; Middle Aged; Pyrazines; Ventricular Premature Complexes | 1997 |
Metabolism of apolipoprotein B in primary moderate hypercholesterolaemia: effects of acipimox and cholestyramine therapy.
Topics: Adult; Apolipoproteins B; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, VLDL; Male; Middle Aged; Pyrazines | 1995 |
Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia.
Topics: Apolipoprotein A-I; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Time Factors; Triglycerides; Uric Acid | 1997 |
Inhibition of lipolysis reduces beta1-adrenoceptor-mediated thermogenesis in man.
Topics: Adrenergic beta-Agonists; Adult; Blood Chemical Analysis; Blood Pressure; Body Temperature Regulation; Carbohydrate Metabolism; Dobutamine; Energy Metabolism; Fatty Acids, Nonesterified; Glycerol; Heart Rate; Humans; Hypolipidemic Agents; Lipid Metabolism; Lipolysis; Male; Pyrazines; Receptors, Adrenergic, beta-1; Respiration | 1998 |
Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids.
Topics: Adult; Analysis of Variance; Area Under Curve; Case-Control Studies; Dietary Carbohydrates; Fatty Acids, Nonesterified; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Tolerance Test; Heparin; Humans; Insulin; Models, Biological; Neurotransmitter Agents; Obesity; Peptide Fragments; Postprandial Period; Pyrazines; Triglycerides | 1999 |
The effect of circulating non-esterified fatty acids on the entero-insular axis.
Topics: Adult; Blood Glucose; Dietary Carbohydrates; Fatty Acids, Nonesterified; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Heparin; Humans; Insulin; Intestines; Islets of Langerhans; Obesity; Peptide Fragments; Protein Precursors; Pyrazines | 1999 |
Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
Topics: Adult; Body Mass Index; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hyperinsulinism; Hypolipidemic Agents; Insulin; Male; Obesity; Pyrazines | 1999 |
Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients.
Topics: Administration, Oral; Adult; Blood Glucose; Body Mass Index; Fatty Acids, Nonesterified; Glucose Tolerance Test; Humans; Hyperthyroidism; Hypolipidemic Agents; Male; Pyrazines; Reference Values; Thyrotropin; Thyroxine; Triiodothyronine | 1999 |
Leptin levels in humans are acutely suppressed by isoproterenol despite acipimox-induced inhibition of lipolysis, but not by free fatty acids.
Topics: Adult; Blood Glucose; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Heparin; Humans; Hypolipidemic Agents; Insulin; Isoproterenol; Leptin; Lipolysis; Male; Pyrazines; Reference Values; Time Factors | 2000 |
Characterization of a G protein-coupled receptor for nicotinic acid.
Topics: Adenylyl Cyclase Inhibitors; Adipocytes; Animals; Binding Sites; GTP Phosphohydrolases; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Hypolipidemic Agents; In Vitro Techniques; Male; Niacin; Pyrazines; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Nicotinic; Spleen; Structure-Activity Relationship; Sulfur Radioisotopes; Tritium | 2001 |
Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance.
Topics: Amyloid; Animals; Blood Glucose; Hypolipidemic Agents; Insulin; Insulin Resistance; Islet Amyloid Polypeptide; Lactic Acid; Lipids; Lipolysis; Liver; Male; Muscle, Skeletal; Peptide Fragments; Pyrazines; Rats; Rats, Wistar; Triglycerides | 2001 |
Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Fatty Acids, Nonesterified; Female; Glucose Intolerance; Glucose Tolerance Test; Hypolipidemic Agents; Injections, Intraperitoneal; Insulin; Mice; Mice, Inbred C57BL; Pyrazines | 2001 |
Short-term Acipimox decreases the ability of plasma from Type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux: a potentially adverse effect on reverse cholesterol transport.
Topics: Animals; Apolipoprotein A-I; Body Mass Index; Carrier Proteins; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Liver Neoplasms, Experimental; Male; Membrane Proteins; Middle Aged; Phospholipid Transfer Proteins; Pyrazines; Rats; Reference Values; Tumor Cells, Cultured | 2001 |
Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.
Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dioxoles; Fatty Acids, Nonesterified; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Male; Obesity; Pyrazines; Rats; Rats, Zucker | 2001 |
Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure.
Topics: Adult; Drug Therapy, Combination; Energy Metabolism; Female; Glucose; Growth Hormone; Hormones; Humans; Hyperinsulinism; Hypolipidemic Agents; Insulin; Lipid Metabolism; Lipolysis; Male; Middle Aged; Pyrazines; Random Allocation | 2001 |
Acipimox stimulates leptin production from isolated rat adipocytes.
Topics: Adipocytes; Animals; Bucladesine; Cells, Cultured; Female; Glycerol; Hypolipidemic Agents; Insulin; Leptin; Lipolysis; Niacin; Norepinephrine; Pyrazines; Rats; Rats, Sprague-Dawley; Stimulation, Chemical | 2002 |
Human serum adiponectin levels are not under short-term negative control by free fatty acids in vivo.
Topics: Adiponectin; Adipose Tissue; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Humans; Intercellular Signaling Peptides and Proteins; Proteins; Pyrazines | 2002 |
Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Dietary Proteins; Energy Intake; Exercise; Fasting; Fatty Acids; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertriglyceridemia; Insulin; Insulin Secretion; Male; Middle Aged; Obesity; Proinsulin; Pyrazines | 2003 |
Molecular identification of high and low affinity receptors for nicotinic acid.
Topics: Amino Acid Sequence; Animals; Cell Membrane; CHO Cells; Cricetinae; Databases as Topic; DNA, Complementary; Dose-Response Relationship, Drug; Female; Furans; Humans; Hyperlipidemias; Hypolipidemic Agents; Inhibitory Concentration 50; Male; Molecular Sequence Data; Niacin; Oocytes; Protein Binding; Pyrazines; Rats; Receptors, Nicotinic; RNA, Messenger; Sequence Homology, Amino Acid; Tissue Distribution; Xenopus | 2003 |
Molecular identification of nicotinic acid receptor.
Topics: Adipocytes; Amino Acid Sequence; Animals; Cell Line; Cloning, Molecular; Colforsin; Cyclic AMP; DNA, Complementary; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Mice; Molecular Sequence Data; Niacin; Open Reading Frames; Poly A; Pyrazines; Radioligand Assay; Rats; Receptors, Nicotinic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Amino Acid; Tissue Distribution | 2003 |
Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Male; Pyrazines; Somatomedins | 2003 |
Modulation of basal glucose metabolism and insulin sensitivity by growth hormone and free fatty acids during short-term fasting.
Topics: Adult; Amino Acids; Blood Flow Velocity; Blood Glucose; Calorimetry, Indirect; Fasting; Fatty Acids, Nonesterified; Forearm; Glucagon; Glucose Clamp Technique; Glycerol; Human Growth Hormone; Humans; Insulin; Insulin Resistance; Lactic Acid; Lipolysis; Male; Microdialysis; Plethysmography; Pyrazines; Somatostatin | 2004 |
Anti-aging effects of anti-lipolytic drugs.
Topics: Aging; Animals; Autophagy; Blood Glucose; Caloric Restriction; Chromatography, High Pressure Liquid; Dolichols; Energy Intake; Fatty Acids, Nonesterified; Hypolipidemic Agents; Insulin; Liver; Male; Pyrazines; Rats; Rats, Sprague-Dawley | 2004 |
Fat oxidation after acipimox-induced reduction in plasma nonesterified fatty acids during exercise at 0 degrees C and 20 degrees C.
Topics: Adult; Bicycling; Blood Volume; Body Temperature; Carbohydrate Metabolism; Exercise; Exercise Test; Fatty Acids, Nonesterified; Heart Rate; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Muscle, Skeletal; Oxidation-Reduction; Pyrazines; Temperature; Triglycerides | 2004 |
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
Topics: Adiponectin; Adult; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Glucose Tolerance Test; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Interleukin-6; Male; Proteins; Pyrazines; Tumor Necrosis Factor-alpha | 2004 |
Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production.
Topics: Adult; Blood Glucose; C-Peptide; Fatty Acids, Nonesterified; Female; Food; Glucagon; Glucose; Glycerol; Humans; Hypolipidemic Agents; Insulin; Kinetics; Lipolysis; Liver; Magnetic Resonance Spectroscopy; Male; Middle Aged; Oxidation-Reduction; Placebos; Pyrazines; Triglycerides | 2005 |
Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox.
Topics: Adiponectin; Adult; Aged; Depression, Chemical; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose Clamp Technique; Half-Life; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Lipolysis; Male; Middle Aged; Pyrazines; Time Factors | 2005 |
[The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Capsules; Delayed-Action Preparations; Dogs; Dose-Response Relationship, Drug; Hypolipidemic Agents; Pyrazines; Random Allocation; Tablets; Therapeutic Equivalency | 2005 |
Inhibition of lipolysis does not affect insulin sensitivity to glucose uptake in the mourning dove.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Columbidae; Fatty Acids; Female; Insulin; Insulin Resistance; Lipolysis; Male; Pyrazines; Tissue Distribution | 2006 |
Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat.
Topics: Animals; Birth Weight; Blood Pressure; Bone Development; Fatty Acids, Nonesterified; Female; Fenofibrate; Growth; Growth Hormone; Hematocrit; Hypolipidemic Agents; Insulin; Insulin-Like Growth Factor I; Liver; Male; Organ Size; Pregnancy; Pyrazines; Rats; Rats, Wistar; Tibia; Weight Gain | 2006 |
Intense [18F]FDG tongue uptake in a case of acipimox-related angio-oedema during FDG-PET myocardial viability study.
Topics: Administration, Oral; Angioedema; Fluorodeoxyglucose F18; Humans; Hypolipidemic Agents; Kidney Neoplasms; Myocardium; Perfusion; Positron-Emission Tomography; Pyrazines; Tongue | 2007 |
Dose-response effects of free fatty acids on amino acid metabolism and ureagenesis.
Topics: Adult; Dose-Response Relationship, Drug; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Forearm; Glucose Clamp Technique; Heparin; Human Growth Hormone; Humans; Lipid Metabolism; Lipolysis; Male; Phenylalanine; Pyrazines; Somatostatin; Tyrosine; Urea | 2008 |
Inflammation and lipid accumulation in xanthoma disseminatum: Therapeutic considerations.
Topics: Adult; Histiocytosis, Non-Langerhans-Cell; Humans; Inflammation; Lipid Metabolism; Male; Pyrazines; Rosiglitazone; Simvastatin; Thiazolidinediones | 2008 |
The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans.
Topics: Alanine Transaminase; Fatty Acids, Nonesterified; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipolysis; Liver; Magnetic Resonance Spectroscopy; Middle Aged; Positron-Emission Tomography; Pyrazines; Triglycerides | 2008 |
Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus.
Topics: Adipose Tissue; Blood Glucose; Blood Pressure; Caloric Restriction; Cholesterol; Diabetes Mellitus, Type 2; Diastole; Fatty Acids, Nonesterified; Glycated Hemoglobin; Heart Rate; Humans; Hypolipidemic Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pyrazines; Triglycerides | 2008 |
Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.
Topics: Adipose Tissue; Animals; Antiretroviral Therapy, Highly Active; Atherosclerosis; Glucose; HIV Protease Inhibitors; Humans; Insulin; Lipids; Lipolysis; Mice; Mice, Knockout; Models, Biological; Pyrazines; Receptors, LDL; Ritonavir | 2009 |
ECG-triggered 18F-fluorodeoxyglucose positron emission tomography imaging of the rat heart is dramatically enhanced by acipimox.
Topics: Animals; Cardiac-Gated Imaging Techniques; Dose-Response Relationship, Drug; Electrocardiography; Fluorodeoxyglucose F18; Glucose; Heart; Male; Positron-Emission Tomography; Pyrazines; Rats; Rats, Wistar; Ventricular Function, Left | 2010 |
The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis.
Topics: Adult; Aged; Arginine; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Insulin; Insulin-Like Growth Factor I; Linear Models; Lipolysis; Male; Middle Aged; Obesity; Pyrazines | 2010 |
Acipimox during exercise points to an inhibitory feedback of GH on ghrelin secretion in bulimic and healthy women.
Topics: Adult; Body Mass Index; Bulimia Nervosa; Case-Control Studies; Exercise; Fatty Acids, Nonesterified; Feedback, Physiological; Female; Gastric Mucosa; Ghrelin; Glycerol; Human Experimentation; Human Growth Hormone; Humans; Hypolipidemic Agents; Neuropeptide Y; Pituitary Gland; Pyrazines; Stomach | 2011 |
Inhibition of lipolysis in Type 2 diabetes normalizes glucose disposal without change in muscle glycogen synthesis rates.
Topics: Adenosine Triphosphate; Blood Glucose; Breath Tests; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glycogen; Humans; Hypolipidemic Agents; Insulin; Lipolysis; Magnetic Resonance Spectroscopy; Male; Middle Aged; Muscles; Pyrazines | 2011 |
Acipimox-enhanced ¹⁸F-fluorodeoxyglucose positron emission tomography for characterizing and predicting early remodeling in the rat infarct model.
Topics: Animals; Diastole; Disease Models, Animal; Fluorodeoxyglucose F18; Hypolipidemic Agents; Male; Myocardial Infarction; Myocardium; Positron-Emission Tomography; Predictive Value of Tests; Pyrazines; Radiopharmaceuticals; Rats; Rats, Wistar; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2012 |
Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms.
Topics: Anti-Inflammatory Agents; Cell Adhesion; Cells, Cultured; Chemokine CCL2; Chemotaxis, Leukocyte; Cyclooxygenase 2 Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; I-kappa B Kinase; Inflammation; Inflammation Mediators; Integrin alpha4beta1; Interleukin-6; Lipopolysaccharides; Monocytes; Niacin; Phosphorylation; Pyrazines; Receptors, G-Protein-Coupled; Receptors, Immunologic; Receptors, Nicotinic; Receptors, Prostaglandin; RNA Interference; Toll-Like Receptor 2; Toll-Like Receptor 4; Transcription Factor RelA; Transfection; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2012 |
Effects of acute and one-week fatty acid lowering on cardiac function and insulin sensitivity in relation with myocardial and muscle fat and adiponectin levels.
Topics: Adipokines; Adiponectin; Adult; Aged; Fatty Acids, Nonesterified; Female; Heart; Heart Function Tests; Hemodynamics; Humans; Hypolipidemic Agents; Insulin Resistance; Lipid Metabolism; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myocardium; Pyrazines; Stroke Volume; Ventricular Function, Left | 2012 |
Acipimox attenuates atherosclerosis and enhances plaque stability in ApoE-deficient mice fed a palmitate-rich diet.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Diet, Atherogenic; Hypolipidemic Agents; Male; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Mice; Mice, Mutant Strains; Palmitates; Plaque, Atherosclerotic; Pyrazines; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2012 |
Antilipolytic drug boosts glucose metabolism in prostate cancer.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Fluorodeoxyglucose F18; Glucose; Humans; Hypolipidemic Agents; Male; Mice; Mice, Nude; Positron-Emission Tomography; Prostatic Neoplasms; Pyrazines; Tissue Distribution | 2013 |
Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects.
Topics: Administration, Oral; Adult; Case-Control Studies; Ceramides; Chemokine CCL2; Diabetes Mellitus, Type 2; Diglycerides; Fatty Acids, Nonesterified; Female; Glucose; Humans; Hypolipidemic Agents; I-kappa B Kinase; Insulin; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Male; Middle Aged; Muscle, Skeletal; Obesity; Pyrazines; Signal Transduction; Toll-Like Receptor 4 | 2013 |
Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals.
Topics: Adult; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Middle Aged; Mitochondria; Obesity; Pyrazines; Reactive Oxygen Species | 2014 |
Assessment of the early stage of cardiac remodeling of spontaneously hypertensive heart failure rats using the quantitative 3-dimensional analysis provided by acipimox-enhanced FDG-PET.
Topics: Animals; Arterial Pressure; Cardiac Catheterization; Disease Models, Animal; Fibrosis; Fluorodeoxyglucose F18; Heart Failure; Heart Ventricles; Hypertension; Imaging, Three-Dimensional; Lipid Metabolism; Male; Positron-Emission Tomography; Predictive Value of Tests; Pyrazines; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke Volume; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Nicotine in combination with a high-fat diet causes intramyocellular mitochondrial abnormalities in male mice.
Topics: Acetyl-CoA Carboxylase; Adipose Tissue; Animals; Body Weight; Diet, High-Fat; Fatty Acids, Nonesterified; Lipolysis; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Mitochondria; Muscle Fibers, Skeletal; Muscle, Skeletal; Nicotine; Obesity; Oxidative Stress; Pyrazines; Risk Factors; Smoking; Triglycerides | 2014 |
Improved mitochondrial function is linked with improved insulin sensitivity through reductions in FFA.
Topics: Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Humans; Insulin Resistance; Male; Mitochondria; Obesity; Pyrazines | 2014 |
Effects of short-term manipulation of serum FFA concentrations on left ventricular energy metabolism and function in patients with heart failure: no association with circulating bio-markers of inflammation.
Topics: Adipokines; Adult; Aged; Biomarkers; Energy Metabolism; Fatty Acids, Nonesterified; Heart Failure; Heart Ventricles; Humans; Hypolipidemic Agents; Inflammation; Insulin; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pyrazines; Tumor Necrosis Factor-alpha; Ventricular Function, Left | 2015 |
Activation of AMPKα2 in adipocytes is essential for nicotine-induced insulin resistance in vivo.
Topics: Adipocytes; Adiposity; AMP-Activated Protein Kinases; Animals; Body Composition; Body Weight; Dual Specificity Phosphatase 1; Enzyme Activation; HEK293 Cells; Homeostasis; Humans; Hypolipidemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Phosphorylation; Pyrazines; Rats; Serine; Smoking | 2015 |
Inhibition of Lipolysis Ameliorates Diabetic Phenotype in a Mouse Model of Obstructive Sleep Apnea.
Topics: Adipocytes; Adiposity; Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Fatty Acids; Gene Expression Regulation; Glucose; Hypoxia; Insulin; Lipolysis; Male; Mice, Inbred C57BL; Phenotype; Pyrazines; Signal Transduction; Sleep Apnea, Obstructive | 2016 |
Inhibition of Lipolysis With Acipimox Attenuates Postburn White Adipose Tissue Browning and Hepatic Fat Infiltration.
Topics: Adipose Tissue; Adipose Tissue, White; Animals; Blotting, Western; Burns; Fatty Acids, Nonesterified; Immunohistochemistry; Lipolysis; Liver; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sterol Esterase; Weight Loss | 2020 |
Growth hormone upregulates ANGPTL4 mRNA and suppresses lipoprotein lipase via fatty acids: Randomized experiments in human individuals.
Topics: Adipose Tissue; Adult; Aged; Angiopoietin-Like Protein 4; Cross-Over Studies; Fatty Acids; Fatty Acids, Nonesterified; Human Growth Hormone; Humans; Hypolipidemic Agents; Hypopituitarism; Lipoprotein Lipase; Male; Middle Aged; Obesity; Pyrazines; RNA, Messenger; Single-Blind Method; Up-Regulation; Young Adult | 2020 |
Acipimox inhibits human carbonic anhydrases.
Topics: Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Dose-Response Relationship, Drug; Humans; Isoenzymes; Models, Molecular; Molecular Structure; Pyrazines; Structure-Activity Relationship | 2022 |
Quantification of Acipimox in Plasma and Tissues by LC-MS/MS: Application to Pharmacokinetic Comparison between Normoxia and Hypoxia.
Topics: Animals; Chromatography, Liquid; Fatty Acids, Nonesterified; Hypolipidemic Agents; Hypoxia; Pyrazines; Rats; Tandem Mass Spectrometry | 2022 |